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ABSTRACT 
 Many cognitive and neurological disorders today, such as Autism 
Spectrum Disorders (ASD) and various forms of epilepsy such as infantile spasms (IS), 
manifest as changes in voltage activity recorded in scalp electroencephalograms (EEG). 
Diagnosis of brain disease often relies on the interpretation of complex EEG features 
through visual inspection by clinicians. Although clinically useful, such interpretation is 
subjective and suffers from poor inter-rater reliability, which affects clinical care through 
increased variability and uncertainty in diagnosis.  In addition, such qualitative 
assessments are often binary, and do not parametrically measure characteristics of disease 
manifestations. Many cognitive disorders are grouped by similar behaviors, but may arise 
from distinct biological causes, possibly represented by subtle electrophysiological 
differences. To address this, quantitative analytical tools - such as functional network 
connectivity, frequency-domain, and time-domain features - are being developed and 
applied to clinically obtained EEG data to identify electrophysiological biomarkers. 
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These biomarkers enhance a clinician’s ability to accurately diagnose, categorize, and 
select treatment for various neurological conditions. 
In the first study, we use spectral and functional network analysis of clinical EEG 
data recorded from a population of children to propose a cortical biomarker for autism. 
We first analyze a training set of age-matched (4–8 years) ASD and neurotypical children 
to develop hypotheses based on power spectral features and measures of functional 
network connectivity. From the training set of subjects, we derive the following 
hypotheses: 1) The ratio of the power of the posterior alpha rhythm (8–14 Hz) peak to the 
anterior alpha rhythm peak is significantly lower in ASD than control subjects. 2) The 
functional network density is lower in ASD subjects than control subjects. 3) A select 
group of edges provide a more sensitive and specific biomarker of ASD. We then test 
these hypotheses in a validation set of subjects and show that both the first and third 
hypotheses, but not the second, are validated. The validated features successfully 
classified the data with significant accuracy. These results provide a validated study for 
EEG biomarkers of ASD based on changes in brain rhythms and functional network 
characteristics.  
 We next perform a follow-up study that utilizes the same group of ASD and 
neurotypical subjects, but focuses on differences between these two groups in the sleep 
state.  Motivated by the results from the previous study, we utilize the previously 
validated biomarkers, including the alpha ratio and the subset of edges found to be a 
sensitive biomarker of ASD, and test their effectiveness in the sleep state. To 
complement these frequency domain features, we also investigate the efficacy of several 
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time domain measures.  This investigation did not lead to significant findings, which may 
have important implications for the differences between sleep and wake states in ASD, or 
perhaps generally for clinical assessment, as well as for the effect of noise on signal in 
clinically obtained data.  
 Finally, we design a similar analysis framework to investigate a set of clinical 
EEG data recorded from a population of children with active infantile spasms (IS) (2-16 
months), and age-matched neurotypical children, in both wake and sleep states. The goal 
of this analysis is to develop a quantitative biomarker from the EEG signal, which 
ultimately we will apply to predict the clinical outcome of children with IS. In addition to 
spectral and functional network analysis, we calculate time domain features previously 
found to correlate with seizures. We compare the two populations by each feature 
individually, test the effects of age on these features, use all features in a linear 
discriminant model to categorize IS versus neurotypical EEG, and test the findings using 
a leave-one-out validation test.  We find almost every feature tested shows significant 
population differences between IS and control groups, and that taken together they serve 
as an effective classifier, with potential to be informative as to disease severity and long-
term outcome.  Furthermore, analysis of these features reveals two feature groups, 
indicating a possibility that these features reflect two distinct qualitative characteristics of 
IS and seizures. 
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CHAPTER I. INTRODUCTION 
1. Motivation 
 At one time all branches of medicine began by classifying disease based on 
reported symptoms and observed clinical signs. During the nineteenth century, medicine 
was revolutionized by the use of objective tests to determine the causes of disease, which 
became a core feature of medicine [1].  While some brain disorders have benefitted from 
this revolution in diagnostic science, others have not. One reason for these difference is 
that brain activity and how it leads to behavior is not well understood.  Current methods 
of diagnosis for neurodevelopmental disorders, such as autism spectrum disorders (ASD), 
rely on self reporting, descriptions of symptoms and clinical behavioral observations, 
while diagnosis of neurological brain disorders such as infantile spasms (IS) are based on 
the subjective evaluations of brain activity recordings by medically trained experts [2–5]. 
These methods allow important decisions and deductions to be made, but the 
heterogeneous presentation of symptoms of most disorders results in an incomplete 
delineations for disorder and subtype classifications. There is a clear need for quantitative 
methods of diagnosis, based on measurable, physical phenomena, such as through 
electroencephalography (EEG), that are directly related to the behavior or affliction of 
interest. In particular, these methods need to be applicable to the less controlled, typical 
clinical settings encountered by patients in need of treatment, rather than those of 
experimental subjects.  Such quantitative biomarkers might not only standardize 
diagnosis, but aid in the selection of treatment, predict prognosis, give insight to severity 
of the condition, identify distinct characteristics, and ultimately allow for relationships 
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between behavior and structural or genetic causes.  The search for such biomarkers is a 
very active area of research.  
This dissertation explores the problem of defining quantitative biomarkers of brain 
disorders from clinically obtained electrophysiological data. We employ mathematical 
tools such as network domain, frequency domain, and time domain methods to clinically 
obtained EEG data recorded from children to infer quantitative electrophysiological 
biomarkers for ASD and IS, and use these biomarkers to attempt to discriminate patients 
from controls. In this chapter, we review relevant literature and background material, and 
then summarize the contents of the dissertation.  
 
4. Biomarkers 
The ‘NIH biomarkers definitions working group’ defines a biomarker as, “a 
characteristic that is objectively measured and evaluated as an indication of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” [6].  As stated above, current clinical parameters for diagnosis and 
phenotypic definitions of brain disorders are highly variable and subjective [7]. In 
addition, much of the quantitative research conducted on conditions such as ASD or IS 
may not be practical for clinical use. Most brain imaging research focused on 
understanding and characterizing cognitive and brain based neurological disease is 
conducted by specialists under highly controlled conditions with state-of-the-art 
equipment. This type of experimentation does not reflect typical clinical efforts to 
diagnose and treat brain disease. In clinics throughout the US and the world, EEG is 
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collected as part of standard practice in diagnosing potential disorders or diseases, in both 
adults and children.  In many of these cases the environment is not perfectly controlled, 
the equipment is generally variable and of relatively low resolution compared to 
specialized experimental recordings methods, the subject is not always willing to 
participate, and patients often do not perform a task specifically designed to highlight a 
suspected condition.  Furthermore, not every clinic has highly specialized medical staff to 
interpret the EEG recordings, and even under the best of circumstances inter-rater 
variability is a common issue for some conditions such as IS [8], so that EEG 
interpretation has been (facetiously) likened to as much of an art as a science.  
Further complicating diagnosis, cognitive and neurological disorders are often 
subtle, and somewhat ambiguously defined. Despite a wide variety of potential biological 
and/or neurobiological causes, brain disorders are usually grouped together by similar 
behavioral signs and symptoms rather than by genetic origin or mechanism.  Because of 
this, finding the singular biological cause of a neurological disorder may be more 
complicated and farther removed from the original disease definition than examining 
functional and electrophysiological activity. Current interpretation of information such as 
electrophysiological activity by clinicians rely heavily on human expertise, however, and 
is inherently subjective.   
Much consideration has gone into the characteristics that are desired from 
biomarkers [6,7,9,10]. First, aside from the information about the disorder of interest, 
biomarkers must also be practically feasible, so that it is possible to collect relevant data 
over a wide variety of settings and locations, across a heterogeneous population that 
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varies by age, developmental level, cognitive ability, and behavioral compliance with 
testing. If the biomarker is feasible, then collection of data from large populations in a 
timely and cost-effective manner is feasible. The biomarker should also be stable and 
robust to influences outside of the experiment, so that the biomarker gives repeatable 
results under noisy.  
In order to address the heterogeneity of both clinical presentation and outcome of 
brain disorders such as ASD and IS, biomarkers must be able to measure quantifiable 
characteristics of a disease through electrophysiological or other physical features.  
Biomarkers should have high sensitivity and specificity to discriminate the clinical 
population from normal. The biomarkers should vary continuously throughout the 
population, and relate to specific traits that can help stratify individuals within a 
diagnostic category, or allow the selective identification of characterizing traits. Ideally, 
biomarkers  guide diagnosis, predict developmental outcomes, and dictate treatment, as 
well as provide information about disease severity, specify the defining traits of a disease, 
identify and characterize subtypes, determine how variations in traits combine to create a 
specific electrophysiological or behavioral outcome, and help postulate the relationship 
between specific electrophysiological activity and biological cause. Biomarkers should 
also be sensitive to meaningful change over time due to intervention, maturation, or 
development. Most importantly, biomarkers must be neurobiologically meaningful, 
grounded in the pathophysiological mechanisms of unnatural development.  
These are ideal characteristics of a biomarker, and though it is not expected that 
early research in biomarkers will achieve all of these traits, it is important to bear in mind 
	  	  
5 
these goals. To achieve these goals and their necessary robustness, we focus our analysis 
on noisy data obtained from clinical, rather than laboratory, observations using standard 
low resolution EEG data, without a constrained task, on children with ASD and IS.   
 
2. Brain Disorders 
ASD and IS are both disorders that can have devastating impacts on their subjects 
and their families, but in different ways. As candidates for mathematical analysis these 
two disorders compliment one another; while IS, like many epilepsies, is reflected by 
often dramatic behavioral and electrophysiological EEG voltage patterns, ASD tends to 
be more ambiguous, both in behavior and in EEG recordings.  
Autism Spectrum Disorder (ASD) is one of the most commonly diagnosed 
neurodevelopmental disorders, and describes a number of conditions characterized by 
social deficits, communication difficulties, and stereotyped, repetitive behaviors [2]. 
Several diagnostic resources are available, all based on behavior, not cause or 
mechanism. Two commonly used diagnostics in autism research are the Autism 
Diagnostic Interview-Revised, a semi-structured parent interview, and the Autism 
diagnostic observation schedule (ADOS), which uses observation and interaction with the 
patient.  The childhood autism rating scale (CARS) is also widely applied in clinical 
environments to assess the severity based on observation. Although the criteria for 
diagnosis is behavioral, and the biological mechanisms of ASD are unknown, several 
studies have found high diagnostic agreement between raters, with the exception of 
atypical autism [11–14].  However, according to DSM-5 ‘very good agreement’ indicates 
	  	  
6 
a kappa coefficient of 0.7 or above, or inter-rater reliability greater than 70% agreement 
[2,15] (kappa is a somewhat disputed statistic used in social sciences describe reliability 
of diagnosis, ranging from a no reliability score of 0 to a 100% agreement score of 1 
[2,15,16]). Yet, almost 60% of children with Asperger disorder first receive an erroneous 
diagnosis of attention deficit disorder, oppositionistic or bipolar disorder [17]. It should 
be noted that there are strong critics of the DSM methodology of inter-rater reliability, 
which adds additional motivation to the need for quantitative biomarkers that objectively 
measure disease characteristics [18]. 
In addition to these broad, somewhat ambiguous categories, ASD has been found 
to be comorbid with a number of other conditions (including epilepsy), and manifests 
dramatically differently from subject to subject, as well as through development and in 
response to intervention.  It is commonly thought of as the final outcome of multiple 
etiological variables, a reflection of heterogeneity in the underlying genetic and/or 
environmental mechanics, which results in heterogeneity of behavioral expression [9].  
This heterogeneity in the manifestation of the disorder as well as the criteria used 
to define it is both motivation for, and an obstacle to, defining a robust and conclusive 
electrophysiological biomarker.  An objective, physically based biomarker would 
eliminate the variability in diagnosis that can result from subjective interpretation of the 
DSM-5 guidelines.  In addition, effective understanding and treatment of ASD would 
benefit from quantitative measures for each of the language deficits, repetitive behaviors, 
and other commonly encountered traits (such as hyposensititivity or hypersensitivity to 
stimuli) that are observed in ASD subjects. These quantitative measures may then be 
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tested for correlation with gene expression, or potentially neuroarchitectural features. For 
example up to 30% of ASD children do not achieve spoken language, even with 
intervention [19]. Standard current clinical metrics for ASD are limited in their ability to 
distinguish pre-verbal from non-verbal subjects, or capture the variability in reading, 
language comprehension, or general cognitive function of these children.  In this case a 
successful quantitative biomarker would gauge the severity of the deficit and inform the 
design of language interventions for individual children. 
In contrast to ASD, the electrophysiological presentation of Infantile Spasms is 
well known, and can be identified in more than 70% of cases [20,21], but can be highly 
variable.  To begin with, IS is generally grouped into three defining categories known as 
symptomatic (indicating that the spasms are secondary to a known neurologic disorder, 
such as tuberous sclerosis, or lesions in some part of the brain), cryptogenic (indicating a 
suspected but not identified neurologic disorder), and idiopathic (indicating no identified 
disorder). IS is highly age dependent, generally occurring by 12 months and disappearing 
by 5 years, though often already having inflicted great damage; even three weeks of 
hypsarrhythmia was found to increase risk of delayed mental outcome [22]. While IS 
children tend to exhibit similar physical behavior traits (tonic seizures, spasms, head 
nodding, torso spasms that often come in clusters of 10-150, up to 30 times a day), the 
gold standard for diagnosis is hypsarrhythmia, or high amplitude slow-wave voltage 
traces, in the EEG record. However, the electrophysiological presentation can be very 
different between patients.  Some patients have what is known as “modified 
hypsarrhythmia”, which is characterized by numerous different, including: less 
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pronounced hypsarrhythmia; multi-focal independent spike discharges;  increased 
interhemispheric synchrony;  asymmetric hypsarrhythmia; hypsarrhythmia with a 
consistent focus of abnormal discharge; hypsarrhythmia with episodes of attenuation;  
hypsarrhythmia comprising primarily high-voltage slow activity with little sharp wave or 
spike activity [23]. There are also rarer cases of IS without hypsarrhythmia [23,24]. The 
ictal EEG recordings may demonstrate electrodecrement, but this is not necessary.  
There are only two treatments that have been found to have some efficacy in 
outcome and IS control: adrenocorticotropic hormone (ACTH) and vigabatrin.  However, 
IS can be caused by a large number of different originating syndromes, and although 
determining the root cause is difficult, the prognosis is highly related to the etiology [24]. 
This substantial variation within IS complicates understanding and treating the disease, 
but as with ASD also provides motivation for objective quantitative measurements, and 
also a mechanism for quantifying different features and potentially correlating them to 
different presentations, and prognoses or outcomes.  The frequent presence of 
hypsarrhythmia not only raises the question of how disparate maladies cause such a 
generally identifiable feature, but motivates the quantitative diagnosis of IS through EEG 
as a measurement device.  
 
5. Electroencephalography (EEG) 
Ultimately diagnosis of brain disorders will probably be best achieved using a 
combination of different measurement tools. Functional magnetic resonance imaging 
(fMRI) is one of the most powerful and commonly used brain imaging tools available, 
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and has provided a wealth of information about many brain pathologies. For example, 
fMRI has indicated the possibility of lower activity in the face fusiform area for ASD 
subjects [25], something not achievable with EEG.   
 However, there are many characteristics of EEG that make it an ideal recording 
method for deriving biomarkers, from a theoretical and practical standpoint.  Unlike 
fMRI, EEG provides a direct measure of postsynaptic neural activity.  It thus has the 
potential to obtain information related to aberrant neural connectivity and network 
activity over the brain. Unfortunately, EEG can only measure the combined post-synaptic 
potentials of neurons perpendicular to the scalp, and is affected by the impedance of the 
skull [26]. It also has fine temporal resolution, allowing the investigation of high 
frequency biomarkers that might otherwise be undetected, as well as the ability to capture 
fleeting and transient events, or other features in the time domain. In addition, EEG is 
relatively easy to record and inexpensive, rendering it widely available and a more 
common source of clinical data than other tools. A particular advantage for investigations 
involving children is that EEG equipment is easily tolerated and allows free movement of 
the subject, in naturalistic settings, which is crucially important for studying 
hypersensitive children. Although motion artifacts are undesirable for EEG data, it is 
much more tolerant of them than fMRI.  
 Part of the benefit of this ease of use is that there is a huge literature of research 
that informs each study.  These reasons motivate that choice of EEG as the primary 
dependent variables for a multisite NIH initiative that aims to spur discovery of new 
medications through identification of brain targets [9]. EEG is well suited to developing 
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complex markers that represent domains of functioning rather than diagnostic categories, 
and which might ultimately connect genes and behavior 
 In our research, EEG data were collected with 19 electrodes using the 
international 10-20 system, which is a common clinical paradigm [23].  In Chapter IV, 
only 12 electrodes were common to all subjects and were analyzed.  In both cases, the 
EEG data were re-referenced from the original reference electrode (usually the neck) to a 
bipolar montage.  While there are many possible reference montages possible, the bipolar 
montage known as the longitudinal or “double banana” is not only the most common in 
clinical EEG diagnosis, but has also been found to be one of the most robust to artifacts 
[26].  
 
6. Mathematical methods 
Many mathematical tools are available to extract features from ASD and IS EEG 
data.  Here we chose those that have shown promise in the analysis of brain voltage 
activity, and are standard and well developed for time series data.  These methods are 
categorized broadly into network analysis measures that focus on brain functional 
connectivity, spectral analyses that focus on brain rhythms, and time domain measures 
that have proven successful in the analysis of human seizure data.  We briefly describe 
these measures here; more details will be provided in each Chapter in which these 
methods are implemented. 
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6.1 Frequency domain analysis 
The power spectrum is one of the most common and powerful methods of 
investigation of frequency specific activity.  A great deal of research has been conducted 
on activity in the canonical frequency bands (i.e., delta 0-4 Hz, theta 4-8 Hz, Alpha 8-13 
Hz, Beta 13-20 Hz, and beyond), and how these rhythms relate to health and disease [27]. 
How distribution of power across frequencies is often the first target for an 
electrophysiological biomarker for both ASD and epilepsy, as well as many other 
conditions. To avoid the contamination of the EEG signal by artifacts, we limited our 
analysis to between 0.5 Hz (to avoid low frequency sweat artifacts) and 25 Hz ( to avoid 
motion artifact which generally occurs at frequencies above 30 Hz., We detail the precise 
method of power spectra calculation in the methods section of Chapter II.  
 
6.2 Network analysis 
There has been a dramatic increase in the analysis of brain activity from the 
perspective of networks and graph theory, for many different modalities including fMRI 
and EEG, applied to many different topics of interest [28].  ASD has recently been 
hypothesized to be a disorder of communication between brain areas rather than a focal 
brain deficit, which makes network analysis a natural choice.  In addition, because 
epilepsy is a disorder that often propagates through different areas of the brain, affecting 
communication, network analysis is a natural choice for studying IS as well [29]. While 
network biomarkers inferred from the EEG will not reveal neural-circuit level differences 
or alterations, they may give insight into specific brain areas that are affected by disease, 
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or if the entire brain is affected. Because we use a small number of nodes in our networks 
(18 for ASD, and 10 for IS, after re-referencing), we are limited to a subset of useful 
network measures.  However, these measures still may contain information relating to 
overall brain activity or communication (e.g., density), or hemisphere specific features 
such as symmetry or interhemispheric connectivity. Both of these have been found to 
have significant differences in ASD and epilepsy.  
Because EEG measures the voltage differences on the scalp and not directly from 
the brain, many possible neural sources may produce the observed EEG activity. A 
potential confound to the analysis of EEG functional networks is the common source 
problem in which a common source can produce the same activity at two sensors, this  
producing a high correlation between these two sensors which may be misidentified as a 
communication between the two areas [30]. We  account for this confound here by 
calculations lag-based cross correlations and omitting any significant correlations at zero-
lag, as described in detail in Chapter II.    
 
6.3 Time Domain Analysis 
Time domain features have been applied to seizure detection for many years. 
While IS EEG data is not typical of other more common epilepsy types, many of the 
proposed seizure detection measures may still reveal important information about IS.  
Hypsarrhythmia is the most common electrophysiological feature in IS EEG, and our 
goal is to find features that will quantify the amount or severity of hypsarrhythmia.  
Hypsarrhythmia manifests as high amplitude slow wave voltages in the delta and theta 
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frequency bands [31]. Therefore it is not unreasonable to anticipate detection of this 
activity using a time domain measure that captures features of the signal amplitude.  For 
example,  the ‘line length’ (known in some fields as the total variation of the signal) is 
computed as the total length between subsequent data points of a voltage, and will then 
be larger during intervals of large amplitude activity. Time domain measures that capture 
the frequency of activity are also natural measures to capture changes in brain activity 
due to epilepsy. For example, the zero crossing rate and the number of local maxima and 
minima in an epoch are related to changes in the frequency of a signal. Besides being 
commonly found in the literature, these metrics also benefit from their simplicity, which 
could increase their applicability to clinical scenarios. These measures are described in 
more detail and applied in Chapter III and IV. 
 
6.4 Feature selection, dimensionality reduction, and classification 
The ultimate test of a biomarker computed using the above methods is the extent to 
which it is able to selectively and specifically distinguish between the clinical and control 
populations. Here we implemented methods to validate proposed biomarkers (Chapter II) 
and applied measures to test classification and reduce the number of features considered 
(Chapter IV). In general, validation and feature reduction are important parts of 
determining the significance of each potential biomarker, not just individually but in 
relation to each other. We note that within study validation is rarely performed in the 
analysis of proposed EEG biomarkers of ASD. In Chapter II, we divide the EEG data 
from an ASD and control population into two groups, for testing and validation of 
	  	  
14 
potential biomarkers. Due to the rarity of IS subjects and the difficulty in collecting these 
data, we did not divide the data into testing and validation groups. Instead, we employed 
a model validation technique and methods of feature reduction, as described in detail in 
Chapter IV. 
 
7. Summary 
These arguments motivation the goal of this thesis: can we find useful 
quantifiable, parametric biomarkers from clinically obtained EEG data, and if so, how?  
The research presented in this dissertation explores different methods and biomarkers 
obtained from analysis of two cognitive/neurological disorders: autism spectrum disorder 
(ASD) and infantile spasms (IS).  The EEG data examined here have been obtained over 
the course of clinical diagnoses of children using low resolution EEG (the standard 
clinical recording with twenty electrode sensors or less), without experimental task, from 
different apparatuses. We apply a variety of mathematical tools to these data in an effort 
to extract meaningful features or biomarkers that directly reflect aspects of the disease 
being examined.  In general, we have opted for direct, interpretable methods rather than 
more complex techniques when feasible. Doing so helps facilitate understanding of the 
connection between disease and measured feature.  In addition, in terms of applicability 
to clinical scenarios and eventual use, a highly specified analysis that uses complex 
mathematical algorithms may be less successfully adopted in general clinical use.   
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8. Summary of dissertation: motivation and approach 
8.1. Chapter II: Robust disruptions in electroencephalogram cortical oscillations and 
large-scale functional networks in autism 
Autism spectrum disorders (ASD) are increasingly prevalent and have a 
significant impact on the lives of patients and their families.  Currently, the diagnosis is 
determined by clinical judgment and no definitive physiological biomarker for ASD 
exists. Quantitative biomarkers obtainable from clinical neuroimaging data – such as the 
scalp electroencephalogram (EEG) - would provide an important aid to clinicians in the 
diagnosis of ASD. The interpretation of prior studies in this area has been limited by 
mixed results and the lack of validation procedures. In Chapter II we use retrospective 
clinical data from a well-characterized population of children with ASD to evaluate the 
rhythms and coupling patterns present in the EEG to develop and validate an 
electrophysiological biomarker of ASD. 
We examine EEG data acquired from a population of ASD (n=27) and control 
(n=55) children 4-8 years old.  Data were divided into training (n=13 ASD, n=24 control) 
and validation (n=14 ASD, n=31 control) groups. Evaluation of spectral and functional 
network properties in the first group of patients motivated three biomarkers that were 
computed in the second group of age-matched patients for validation. 
Three biomarkers of ASD were identified in the first patient group: (1) reduced 
posterior/anterior power ratio in the alpha frequency range (8-14 Hz), which we label the 
“peak alpha ratio”, (2) reduced global density in functional networks, and (3) a reduction 
in the mean connectivity strength of a subset of functional network edges.  Of these three 
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biomarkers, the first and third were validated in a second group of patients. Using the two 
validated biomarkers, we were able to classify ASD subjects with 83% sensitivity and 
68% specificity in a post-hoc analysis. 
The work in Chapter II corroborates the general finding that ASD subjects have 
decreased alpha power gradients and network connectivities compared to control 
subjects.  In addition, Chapter II demonstrates the importance of validating EEG 
biomarkers identified using exploratory methods. 
 
8.2. Chapter III: Analysis of scalp EEG data recorded from patients with ASD during 
sleep 
Analysis of brain activity in health and disease during sleep is an important 
complement to investigations of the awake brain. Previous research suggests that ASD 
subjects show marked differences from control subjects in sleep [32–36]. However, in 
Chapter II we showed that although two validated biomarkers for ASD occur in the wake 
state, preliminary results did not find significant differences in the stage-2 sleep data 
when analyzing coherence, cross-correlational network density, or spectral power. 
In Chapter III we further examine the ASD biomarkers during two additional 
sleep states, stage-1 and stage-3, and analyze new biomarkers for all wake and sleep 
states.  We examine inter-hemispheric and anteroposterior connectivity, an index of 
interhemispheric symmetry known as the brain symmetry index (BSI), and several time 
domain features commonly used in seizure detection, and which reflect characteristics 
such as high voltage amplitude and noise in data.  These features are the zero-crossing 
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rate, which has been considered to be a simple and easy measure of signal noise [37]; the 
number of local maxima and minima, which reflects the level of oscillations in the signal; 
the line length, which is the summation of the distance between each consecutive data 
point, also known as the total variation of the signal; and the root mean squared 
amplitude, which measures the average amplitude of the voltage trace in an epoch.  
We find no significant differences using any of these features for any of the sleep 
states, nor for the wake data, except for the two biomarkers we discuss in Chapter II.  
While no new biomarkers for ASD are found, we interpret these negative results, both 
clinically and scientifically, and propose how these results are informative to ASD 
research.  
 
8.3. Chapter IV: Infantile spasms characterized by EEG cortical voltage oscillations 
Infantile spasms (IS) is a rare but devastating disease whose outcome correlates 
both with the treatment of spasms and the abnormal EEG background. IS EEG is 
characterized by a triad of high amplitude, chaotic activity with multifocal spikes 
(hypsarrhythmia) and intermittent ictal electrodecrements. More often than not, IS EEG 
is characterized as modified hypsarrhythmia as one or more of these features may be 
absent, so that IS EEGs do not have a stereotyped background but show significant 
variability between subjects.  In addition, EEG classification is typically subjective; the 
classification is binary as either showing hypsarrhythmia or not, without quantification of 
the amount or severity of hypsarrhythmia within the EEG. A more quantitative estimate 
of hypsarrhythmia and features would allow for more precise estimation of IS severity, 
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response to treatment, deterioration and correlation between extent of background 
abnormality and outcome. 
Chapter IV describes the evaluation of EEG data from children with active 
infantile spasms, compared with age matched neurotypical children aged 2-16 months. 
The measured features expected to capture the characteristics of hypsarrhythmia 
background include: a) network features, b) frequency domain features, and c) time 
domain features. We use a 10-fold validation to test performance in categorizing IS 
versus control EEG. We then use the estimator to quantify the percent of EEG epochs 
with hypsarrhythmia compared to estimates by a neurophysiologist.  
We find that the hypsarrhythmia estimator categorizes EEGs with hypsarrhythmia 
with greater than 84.3% sensitivity and 97.8% specificity. The proposed automated 
detector of hypsarrhythmia and estimate of degree of abnormality is a step towards 
quantitative measures of clinical epilepsy diagnosis and treatment. 
 
8.4. Chapter V: Conclusion 
 We conclude by summarizing the main research results, discussing the 
implications for the broader medical and scientific communities, and proposing future 
directions of research.  
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CHAPTER II. ROBUST DISRUPTIONS IN ELECTROENCEPHALOGRAM 
CORTICAL OSCILLATIONS AND LARGE-SCALE FUNCTIONAL 
NETWORKS IN AUTISM 
This chapter is adapted from the publication: Matlis, S., Boric, K., Chu, C. J., & Kramer, 
M. A. (2015). Robust disruptions in electroencephalogram cortical oscillations and large-
scale functional networks in autism. BMC Neurology, 15, 97. 
 
1. Introduction 
 
Autism Spectrum Disorders (ASDs) are a group of disorders characterized by 
impairment in communication, and social interaction, rigidity of interests, and repetitive 
stereotypical behaviors [38].  First characterized as a behavioral disorder in 1943, the 
diagnosis of autism appears to be increasing, from less than 3 per 10,000 in the 1970’s to 
more than 30 per 10,000 in the 1990s [39].  In 2012, the Centers for Disease Control 
reported a frequency of 1 in 88 children [40,41]. The symptoms and severity of ASD 
varies significantly, and mild symptoms or those masked by other handicaps may go 
unrecognized. Appropriate treatments, especially in children, have been found to lead to 
improved prognosis [42,43], which has motivated the search for biomarkers that can 
assist identification of ASD in children [44–46]. 
Because ASDs are defined by behavioral traits, the diagnosis relies on 
questionnaires and observation. Multiple genetic and biological risk factors have been 
identified [43], however isolating a common metabolic or genetic pathophysiology 
leading to the ASD phenotype has proven difficult [47]. An alternate approach is to 
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measure differences in observable brain function.  There is a growing consensus that 
ASD is characterized by an impairment in the communication between brain areas, rather 
than a deficit in a localized brain region [48–58].  Advances in neuroimaging and signal 
processing allow for inference and analysis of functional brain networks, which represent 
the dynamic relationships between activity recorded in different brain regions [59]. 
Analytical methods derived from the field of graph theory allow measurement and 
comparison of functional networks in health and disease [50,60–62].  While functional 
magnetic resonance imaging (fMRI) has received much attention as a tool for 
investigating functional brain networks derived from hemodynamic signals, the scalp 
electroencephalogram (EEG) provides several distinct advantages at it is less expensive, 
less intrusive, less affected by head motion artifacts, and provides a direct measure of 
brain voltage activity.  In addition, the EEG provides exquisite temporal resolution, 
allowing for investigation of cortical rhythms, as characterized in the power spectra, 
which have also been associated with brain function and dysfunction [63].  Thus, EEG 
provides benefits as a complimentary tool to fMRI, with advantages for use in children 
with autism in particular.   
Despite these powerful tools, both EEG and fMRI research of ASD have so far 
produced varied and sometimes contradictory results.  Arguably the most consistent 
finding is a reduced level of coupling in activity of ASD subjects between ‘long range’ 
areas [49,53,56,64–78], though even this finding is not universal [32,79–86]. ‘Short 
range’ coupling has been found to be both greater [49,71,74,76] and lower [64–
66,68,69,81,84,85,87,88] in ASD subjects compared to control subjects. While a number 
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of studies report seemingly similar results, all previously reported studies have used 
exploratory methods with results found using different techniques, limiting interpretation 
and cross-study validation. Post-analysis validation has not been employed in existing 
studies of ASD biomarkers, but is an important step to separate statistically robust 
findings from chance observations.  Without a consensus on particular measures 
associated with ASD or its individual characteristics, the search for definitive, 
physiological biomarkers of ASD continues.   
In this study, we use spectral and functional network analysis of clinical EEG data 
recorded from a population of children to propose a cortical biomarker for autism.   We 
first use an exploratory dataset of age-matched (4-8 yr) ASD and neurotypical children to 
develop hypotheses based on analysis of power spectral features and measures of 
functional network connectivity. From the exploratory group of subjects, we derive the 
following hypotheses: 1) The ratio of the power of the posterior alpha rhythm (8-14 Hz) 
peak to the anterior alpha rhythm peak is significantly lower in ASD than control 
subjects. 2) The functional network density is lower in ASD subjects than control 
subjects. 3) A select group of edges provide a more sensitive and specific biomarker of 
ASD.  We then test these hypotheses in a validation dataset of subjects and show that 
both the first and third hypotheses, but not the second, are validated.  These results 
provide a validated study for EEG biomarkers of ASD based on changes in brain rhythms 
and functional network characteristics.  
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2. Methods 
 
2.1 Subjects and EEG recordings 
All subjects ages 4-8 years diagnosed with ASD by a specialist in child 
neurology, child psychiatry, or developmental pediatrics, and with an EEG obtained 
between 2/1/2002-4/1/2011 in the neurophysiology unit at Massachusetts General 
Hospital were retrospectively identified. In order to reduce variability in the ASD group, 
subjects diagnosed with epilepsy or found to have epileptiform activity on EEG were 
excluded from analysis. For control data, subjects age 4-8 years with normal EEG 
recordings (as defined by clinical electroencephalographers independent from this study) 
were retrospectively identified from recordings performed at Massachusetts General 
Hospital between 2/1/2002 and 4/1/2011. Clinical chart review was performed and only 
those children with documented normal neurodevelopment and non-epileptic events 
without known EEG characteristics were included in the control group for analysis. For 
both the ASD group and control group, neurodevelopmental status was determined from 
chart review of the clinical assessments just prior to or following the EEG recording. 
Active medications at the time of EEG include in the ASD training data, one subject was 
taking 0.1mg of Clonidine and one subject was taking 20mg of Ritalin, and in the ASD 
validation data one subject was taking 0.05mg Clonodine and 0.5mg Risperdal.  Of the 
control subjects, no medications were taken in the training group, and in the validation 
group one subject was taking 50mg of Amitriptyline, and one subject took 0.05mg of 
Clonidine prior to the EEG. Twenty-seven children with ASD (25 M and 2 F) and fifty-
five controls (29 M and 26 F) were included for analysis. In the ASD training group 
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(defined below), one subject had ADHD and one reported headaches.  In the ASD 
validation group (defined below), three subjects had ADHD - one of which had 
depression, and one of which had tics – while one other subject had only tics, another 
subject had ADD, and another subject had anxiety.  Of the 55 neurotypical controls, 13 
had migraines or other headache syndromes, 9 had a syncopal event, 8 had tics, 4 had 
anxiety, 1 had sleep apnea, 1 had breath holding spells, and 1 had essential tremor. 
Although formal scales of ASD severity were not used in this population, chart review of 
physical exam and clinical assessments was performed retrospectively by a board 
certified child neurologist (C.J.C.). Using the DSM 5 criteria, severity was estimated as 
follows: in the training group of thirteen ASD subjects: eight mild, four moderate, and 
one severe ASD.  In the validation group of fourteen ASD subjects: five mild, three 
moderate, and six severe ASD.    
In an effort to identify a clinically feasible and relevant EEG biomarker for ASD, 
we utilized routine EEG recordings following standard clinical recording techniques. All 
children were given the same instructions prior to the evaluation, including 
recommendations for mild sleep deprivation (awaking the child 2-4 hours prior to regular 
morning arousal).  In our dataset, sleep was recorded in 18/27 ASD subjects and 45/55 
healthy controls.  In all cases with a sleep recording, sleep onset was within 40 minutes of 
the start of the EEG recording session. In all cases, the wake EEG was obtained first and 
a posterior dominant rhythm was obtained during a period of quiet restfulness with eyes 
closed. For recordings of quiet wakefulness, patients were recorded in a quiet room 
without active stimulation. 
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Recordings included electrooculogram (two channels), scalp EEG (19 Ag/AgCl 
electrodes placed according to the 10–20 international system: FP2, F4, C4, P4, O2, F8, 
T4, T6, Fz, Cz, Pz, Fp1, F3, C3, P3, O1, F7, T3, and T5) and electrocardiogram using a 
standard clinical recording system (Xltek, a subsidiary of Natus Medical). Signals were 
sampled at 200, 256, 500 or 512 Hz and stored on a local server. Analysis of the data 
from these subjects was performed retrospectively under protocols approved and 
monitored by local Institutional Review Boards according to the National Institutes of 
Health guidelines. 
 
Table II.1. Patient Demographics 
Group Age 4 Age 5 Age 6 Age 7 Age 8 Total 
ASD Training 2M 2M, 1F 4M 3M 1M 12 M, 1 F 
ASD Validation 1M 2M 4M 5M, 1F 1M 13 M, 1 F 
Control Training   --   3F 4M, 1F 5M, 1F 3M, 3F 1M, 3F 13 M, 11 F 
Control Validation 4M, 2F 3M, 3F 4M, 1F 2M, 5F 3M, 4F 16 M, 15 F 
 
Prior to analysis, subject datasets were divided into two groups, one group for 
exploratory analysis and hypothesis creation and a second group for hypothesis 
validation.  The subjects in each group were selected to preserve approximately similar 
age distributions in each group (Table 1).  In this way, hypotheses generated in the first 
group were tested, and validated or disputed in the second group, thereby controlling for 
spurious findings due to type I error.  EEG recordings were manually reviewed by an 
experienced electroencephalographer (C.J.C.) and large movements and muscle artifact 
removed.  Wake and non-rapid eye movement (NREM) sleep intervals were identified by 
visual analysis as per standard criteria [89].  Only patients with at least 100s of artifact-
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free EEG data were included in the exploratory group (13 ASD, 24 Control) and 
validation group (14 ASD, 31 Control).  
 
2.2 Data preprocessing for network and spectral analysis. 
For network analysis, the EEG data were filtered with a 3rd order Butterworth, 
zero-phase filter (notch filtered at 60 Hz to remove line noise, high pass at 0.5 Hz to 
avoid slow drift, and low pass at 50 Hz to avoid higher-frequency line noise harmonics).  
Because the EEG data were selected to avoid large movements and muscle artifact, 
noncontiguous points occurred; we removed 0.5 s from both sides of each noncontiguous 
point before further analysis.  Visual analysis and a simulation study (not shown) 
confirmed that this removal was sufficient to mitigate artifacts produced at the 
noncontiguous points during the filtering process. For spectral analysis, the EEG data 
were not filtered, but 0.5 s was removed from each noncontiguous point to maintain 
consistency with the network analysis.  In order to optimize near-field activity and reduce 
electrical contamination from the physical reference, both filtered and non-filtered data 
were then re-referenced according to the longitudinal bipolar (‘double banana’) montage, 
leaving 18 bipolar signals (‘derivations’) in place of the original 19 electrode signals. 
This reference montage was chosen in lieu of other popular montages such as the 
common average or Hjorth-Laplacian references because of its effectiveness and 
widespread clinical usage.  While the common average reference and spline Laplacian 
reference perform reasonably well when used with a large enough number of electrodes 
(e.g., 128 or more), these references are expected to perform poorly when applied to the 
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standard, low density 10/20 electrode system (see [26], page 295).  In addition, the 
common average reference has been found to increase spurious coupling in some cases 
[90].  In contrast, bipolar montages are considered one of the best available options to 
improve spatial resolution in EEG with a limited number of electrodes (see [26], p. 291).  
Hjorth (or nearest-neighbor) Laplacian is closely related, however we chose the double 
banana montage due to its extensive use clinically.   
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Figure II.1. Construction of power ratio and functional networks from multivariate scalp EEG recordings. 
Ai. Example EEG data from re-referenced 18 channels (broadband, 0.5 - 50 Hz) 
according to the bipolar “double banana” montage.  Filtered and unfiltered data are 
divided into 2s epochs.  Aii. From unfiltered data power spectra are calculated for each 
channel using the multitaper method. Aiii. The ratio of power spectra are obtained from 
the power spectra of the posterior four derivations (T5-O1, P3-O1, P4-O2, T6-O2) 
divided by the anterior four derivations (Fp1-F7, Fp1-F3, Fp2-F4, Fp2-F8).  Shown here 
is the mean posterior/frontal power spectra ratio to illustrate the properties of the peak 
alpha-ratio statistic. 
B. For each channel pair filtered data (0.5 - 50 Hz) from 2s epochs are used to calculate 
the cross-correlation. Two example traces for Fp2-F8 and T4-T6 show a correlation here 
with maximal coupling at a time lag of -50 ms.  The significance of the maximum 
absolute value of the cross-correlation (blue circle) is determined using an analytic 
procedure (see Methods).  
C. Example binary coupling networks derived from four 2-s epochs. Significant electrode 
coupling is represented in blue and indicated with an edge. These networks are averaged, 
resulting in a weighted coupling network for each subject. These are then compared 
against bootstrapped edge weight distributions in (D).  
D. To create bootstrapped edge weight distributions, surrogate networks mirroring the 
original datasets are created by randomly sampling functional networks with replacement 
from all epochs of all subjects of both groups. Original ASD and control edge weights are 
compared to the surrogate edge weight distributions, and edges most significantly outside 
the distribution (p<1/100,000) are selected to make a mask of highly significant edges.  
This mask is used to select the edges with the greatest difference between the ASD and 
control groups.   
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All EEG data were then divided into non-overlapping windows of 2 s duration 
(windows containing concatenated data from noncontiguous time points were discarded).  
We use 2 s intervals to approximately maintain stationarity in the time series (which 
requires short epochs) while keeping sufficient data for accurate coupling estimates 
(which requires long epochs). Finally, we normalized the data from each electrode within 
each window to have zero mean.  All data preprocessing and subsequent analysis were 
performed using custom software developed in MATLAB.     
 
2.3 Spectral analysis procedure 
For the spectral analysis of the unfiltered data, the power spectrum for each 2 s 
epoch was computed using the multitaper methods implemented in the Chronux toolbox 
[91] with 5 tapers and a time-bandwidth product of 3, so that the resulting frequency 
resolution was 1.5 Hz. Frequencies below 0.5 Hz were omitted to avoid low-frequency 
drift in the data. For each subject this resulted in a power spectrum for each of the 18 re-
referenced signals, for each 2 s epoch.   
To characterize the power spectra for each patient we computed a summary 
statistic – the “peak alpha-ratio” – as follows. First, we computed the power spectrum of 
each signal for each epoch of the dataset, and then averaged the power spectra across all 
epochs.  Second, we computed the ratio of this average power between four pairs of 
posterior to anterior signals (Far Left: T5-O1/Fp1-F7; Medial Left: P3-O1/Fp1-F3; 
Medial Right: P4-O2/Fp2-F4; Far Right: T6-O2/Fp2-F8).  Third, we determined the 
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maximum value of the ratio within the alpha frequency range (8-14 Hz) for each of the 
four channel pairs.  These four maximum back/front ratios were then averaged to produce 
the summary statistic, mean “peak alpha-ratio”, for each patient.  We choose to compute 
the spectral ratio for three reasons.  First, the posterior to anterior alpha gradient is one of 
the most widely observed EEG features in healthy controls and thus is an intuitive feature 
to evaluate in a disease population [23]. In addition, this metric has been previously 
correlated with behavioral inhibition and sociability [92,93]. Second, as described in 
Results, changes in power (not the ratio) between the ASD and control subjects at all 
electrode deviations reveal no significant differences. Third, we choose to compute the 
frontal/posterior ratio to normalize the spectral results of each individual subject. This 
choice of normalization protects against artifacts that impact the overall amplitude of 
voltage activity for each subject (e.g., a subject with thicker hair may be expected to have 
reduced electrode conductance and an overall reduction in EEG amplitude), and we 
expect this normalization to make the results more robust to changes in clinical settings 
and routine (e.g., to changes in electrode recording equipment).  
 
2.4 Functional network inference and measures 
While there are many approaches to determining functional connectivity from 
time series data [94], including multiple coupling measures (e.g., linear or non-linear) and 
different strategies for determining network edges, we selected a simple measure of linear 
coupling: the cross correlation. The cross correlation is a bivariate measure of linear 
association between two brain regions, and serves as a basic measure of electrocortical 
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functional connectivity [61,95]. We note that most linear and nonlinear measures appear 
to perform equally well on simulated and observed macroscopic brain voltage data 
[96,97].   
Each subject possessed at least 50, 2-second epochs of data (min 57, max 1256, 
mean 254), which is sufficient to support stable functional network representations [98–
100].  To create functional networks, we follow the procedure outlined in [101] and 
applied in [98–100].  We briefly describe this procedure here.  For each patient, we create 
a functional network for each 2 s epoch of filtered data using the 18 derivations (signals) 
of data, based on the cross correlation of the data between each pair of derivations.  We 
note that each signal in each 2 s interval is normalized by its variance (or total power) 
before performing the correlation analysis.  Doing so reduces the differences in amplitude 
between signals and mitigates a potential confounding factor in the correlation analysis 
[102]. In addition, we show in Results that differences in correlation between the ASD 
and control subjects are not accompanied by changes in the (absolute) EEG power in the 
2.5-17.5 Hz range (i.e., the broad, low frequency range which dominates the correlation 
measure). This observation suggests that changes in EEG power (i.e., in the signal to 
noise ratio) do not confound the functional connectivity results, in accordance with 
[102,103]. We use the maximum absolute value of the cross correlation over time lags of 
±500 ms to measure the coupling (which encompasses the duration of known 
neurophysiological processes and cross-cortical conduction times [104,105]).  To assess 
the variability of the cross correlation across lags, we compute the average variance of 
the cross correlation between all derivation pairs and all 2 s epochs for a subject; this 
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provides a common measure of variability that we apply to assess the significance of each 
correlation statistic (see [101]). 
For each 2 s epoch, an undirected binary functional network is inferred from these 
correlations based on their significance.  Each node represents a derivation (e.g., channel 
T5 – channel O1), an edge value of 1 represents a statistically significant correlation 
between the two derivations, and an edge value of 0 indicates a weaker correlation.  To 
correct for the multiple significance tests within each 2 s epoch, we use a linear step-up 
procedure controlling the false detection rate (FDR) with q = 0.05. For this choice of q, 
5% of the network connections are expected to be falsely declared [106]. This procedure 
results in a thresholding of the significance tests of the correlation — not of the 
correlation value itself — for each 2 s epoch [101].  The networks obtained in this 
manner have an associated measure of uncertainty, which is the expected number of 
edges incorrectly declared present. 
To mitigate the impact of volume conduction [26,95] on the functional network 
analysis, we identified the correlations deemed significant at zero lag, and removed these 
edges from the analysis.  In doing so, we expect to remove both spurious correlations due 
to volume conduction and true correlations that occur at zero lag; in this sense, this 
procedure is conservative.   This approach has an added benefit of reducing the effect of 
montage selection, whereby subtraction of signals may result in spurious coupling 
between derivations that share electrodes.   
To assess the network structure, we apply two measures of network connectivity 
[60].  The density for each network is calculated in the standard way as the number of 
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edges detected (at non-zero lag) divided by the total number of possible edges (153 minus 
the number of spurious edges detected at zero lag).  The mean density for each subject is 
calculated as the average density across all epochs for the subject.  The mean density for 
each group (ASD and control) is calculated as the mean of the subject densities within 
each group.  The degree is also calculated in the standard way as the number of edges that 
connect to each node, and average degree values for a subject and group are calculated in 
the same way as the average density values.  
In addition to correlation networks, we also computed networks with a second 
measure of linear association - the coherence, estimated using the multi-taper method 
[107].   As for the correlation networks, we inferred coherence networks for all derivative 
pairs over 2 second epochs.  To calculate a p-value to identify significant edges in the 
coherence networks, we first transformed the coherence, C, to the quantity 
(ν0−1)|C|2/(1−|C|2), which has an approximate F-distribution with two and ν0−2 degrees 
of freedom under the null hypothesis of no coherence. Here, ν0 is twice the number of 
tapers, either 10 or 16. We then corrected for multiple significance tests using a linear 
step-up FDR controlling procedure with q = 0.05. Coherence networks were computed 
for four electrode montages - double banana, transverse, Hjorth Laplacian, and neck 
reference – and for both sleep and wake data, at 4 frequencies with 5 Hz bandwidth and 8 
tapers (centers at 3.5 Hz, 8.5 Hz, 13.5 Hz, and 18.5 Hz) and 8 frequencies with 3 Hz 
bandwidth and 5 tapers (centers at 2.5 Hz, 5.5 Hz, 8.5 Hz, 11.5 Hz, 14.5 Hz, 17.5 Hz, 
20.5 Hz, and 23.5 Hz). However, we found no significant differences in density between 
	  	  
33 
the ASD and control groups in the exploratory analysis, and the analysis of coherence 
networks was not continued in the validation dataset. 
 
2.5 Bootstrap test for significantly different edges 
With the aim of developing a biomarker for ASD, we sought to assess the 
difference in network structure between the ASD and control groups.  While a network-
wide measurement such as the density is informative, a measure that localizes differences 
between ASD and control networks to more specific connections (e.g., network edges) 
would provide additional information. Knowledge of specific edge differences would 
allow us to focus on just these edges, reducing noise introduced by non-informative 
edges, and potentially producing a more sensitive and specific biomarker.  
To that end, a bootstrap analysis was performed to test whether a significant 
difference occurs between the ASD and control groups in the appearance of each edge. 
We began with the null hypothesis that no difference exists between the two populations.  
We then created surrogate data for each subject by randomly drawing with replacement 
functional networks (each derived from a 2 s epoch) from the combination of all ASD 
and control subjects.  This process of generating surrogate data was then repeated for all 
subjects. In this way, the surrogate data for each subject of each group was created.  If the 
null hypothesis is correct, we should find no statistically significant differences between 
the network features deduced from the original ASD and control groups compared to the 
surrogate data.   
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We repeated this process of generating surrogate data and computing network 
measures 100,000 times to create a distribution of average edge weights for each edge in 
the ASD group and in the control group.  For each of the 100,000 surrogates of both 
groups, 153 average edge weights were calculated (one for each node pair).  We note that 
the average edge weights were calculated in the same way as for the original data; that is, 
for each subject we computed an average network across the 2 s epochs, and then these 
subject networks were averaged to produce a population average network for the ASD 
group, and a population average network for the control group. The 100,000 surrogates 
correspond to 100,000 population average networks for the ASD group, and 100,000 
population average networks for the control group. In these surrogate data, the 100,000 
values for each edge weight establish the bootstrap distributions of the edge weights for 
the ASD group and control group. 
We then compared each observed average ASD edge weight to the corresponding 
surrogate ASD distribution, and each observed average control edge weight to the 
corresponding surrogate control distribution.  This bootstrapping allows us to examine 
each edge individually, and to determine the statistical significance of particular edges in 
the ASD and control groups.  Finally, we determined the subset of edges identified as the 
most significantly different in the observed data compared to the surrogate data.  In 
practice, these edges were associated with the smallest p-values detectable in the 
bootstrap procedure (p < 10-5).  The edges identified in this way were used to generate a 
“mask”, or selection of edges most significantly different from the bootstrap distribution, 
with the purpose of developing a biomarker of ASD.  
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2.6 Classification of datasets 
We also performed a discriminant analysis to classify the validation subjects into 
ASD and control groups.  To do so, we used the MATLAB function classify, selecting 
the classification option ‘quadratic’; in this method, a discriminant function fits a 
multivariate normal density to each group, with covariance estimates stratified by group.  
We trained the classifier on the first group of ASD and control subjects, and tested the 
classifier on the second group of validation subjects using the two validated significant 
quantitative measures identified in the training data (peak alpha ratio and mask density, 
i.e., the mean weight of a subset of edges).  
 
3. Results 
In this section, we describe the application of spectral and network analysis to 
EEG data recorded from ASD and control subjects. Using an initial exploratory analysis 
on a subset of ASD and control subjects, we build hypotheses that we then test in a 
second group of ASD and control subjects.  In this way, we identify and validate two 
biomarkers of ASD that can be inferred from standard EEG clinical recordings. Below 
we briefly review the exploratory measures tested and then describe in detail the 
measures tested on the validation dataset. In the spectral analysis, we focus on a measure 
of the antero-posterior spectral power gradient, a metric previously correlated with 
behavioral inhibition and sociability [92,93].  In the network analysis, we first examine 
the network density.  We then examine node degree to determine if the differences in 
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density are driven by a subset of spatial locations, or are a property of the entire network.  
We next identify a subset of edges that appear significantly more common in the control 
group, and significantly less common in the ASD group. These select edges provide a 
subset of highly significant edges to apply in a biomarker.  Finally, we attempt to classify 
the two populations in the validation group using a subset of measures deduced from the 
training group.   
 
3.1 Spectral analysis reveals an alpha-band biomarker of ASD. 
To assess rhythmic activity in the EEG data, power spectra were computed from 
numerous short epochs (Fig 2, also see Methods: Spectral analysis procedure). Visual 
inspection of the average power spectra during wakefulness suggests differences between 
the ASD and control groups (Fig 2A, top two rows):  the anterior power spectra have 
higher mean power in the ASD subjects (blue) than the control subjects (red) at alpha 
frequency and above (plateauing near 20 Hz).  In addition, visual inspection suggests that 
both ASD (blue) and control (red) subject population mean power spectra possess a broad 
peak in the alpha frequency range (~10 Hz) in the posterior four channels, consistent with 
the well characterized posterior dominant alpha rhythm present in quiet wakefulness 
[108,109].  We note that visual inspection of the power spectra of the posterior four 
derivations reveals a larger peak in alpha power of the control subjects (Fig 2A, red) 
compared to the ASD subjects (Fig 2A, blue).  
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Figure II.2. Posterior to anterior power spectra ratio differs significantly between ASD and control groups.  
A. Power spectra of ASD and control groups recorded at the anterior (Fp1-F7, Fp1-F3, 
Fp3-F4, Fp2-F8) and posterior (T5-O1, P3-O1, P4-O2, T6-O2) nodes, calculated for each 
2-s epoch, and averaged over all epochs. Training group analysis (top) and validation 
group analysis (bottom). Dash-dot lines represent two standard errors of mean. Power in 
units of 10log10(µV2/Hz). 
B. Averaged power spectra ratio between posterior and anterior channels (i.e., T5-
O1/Fp1-F7) averaged over epochs and computed at four locations, then averaged over 
subjects to create a group average for the training (top) and validation (bottom) groups.   
Upper and lower 95% confidence bounds indicated by dotted blue (ASD) and dotted red 
(control) lines. This result motivated the creation of the peak alpha-ratio statistic (Fig 
2C). 
C. For each epoch, the maximum values were obtained of the four power ratios, in the 
alpha frequency band, and averaged.  These ratios were then averaged over all epochs for 
each subject in the ASD (blue, Asperger’s in green) and control (red) groups.  The peak 
alpha ratio is lower in the ASD group in the training (p≤0.0034) and validation data (p ≤ 
0.0025).  Error bars represent two standard errors of the mean. 
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To characterize these differences in power, for each subject in the exploratory group 
we calculated the mean power from 2.5 Hz to 17.5 Hz, in steps of 3 Hz.  We note that this 
analysis covers frequencies across the classically defined frequency bands.  We omitted 
higher frequencies due to the increased relative impact of muscle artifact in those ranges 
[110]. Using this metric, over these 6 frequencies and 18 derivations, we found 9 
significantly different power values between the ASD and control populations out of 108 
comparisons (significances ranged from p = 0.0099 to 0.0459).  When corrected for 
multiple comparisons using a False Detection Rate (FDR) control, no significant 
differences remained. We also computed power spectra for NREM sleep data in the 
exploratory group, but found by visual inspection that the mean power spectra for the 
ASD and control populations at each derivation overlapped.  We therefore did not 
explore the sleep data further.  
Because no significant differences were found at individual derivations, we 
considered ratios of power.  Absolute differences in mean power are expected to be 
muted by our normalization procedures, however power ratios will not be affected. 
Population differences in the anterior and posterior derivations are enhanced in the 
averaged posterior/frontal spectral ratios (Fig 2B).  Visual inspection of the spectral ratio 
of posterior derivations to frontal derivations averaged across derivations and subjects 
revealed a peak most prominent in the alpha band.  In the exploratory group, the ratios 
exhibit a sharp peak near 10 Hz for both control (Fig 2B, red) and ASD (Fig 2B, blue) 
subjects, and the peak is visibly larger in the control group compared to the ASD.  To 
further characterize these results beyond visual inspection, we calculate a single measure, 
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here labeled the “peak alpha ratio”.  This measure focuses on the antero-posterior EEG 
spectral power gradient, and provides a numeric summary statistic to compare the ASD 
and control groups.  The peak alpha ratio is calculated for each subject at every 2 s epoch 
as follows (for detailed description, see Methods: Spectral analysis procedure).  Power 
spectra are averaged over all epochs, and then the four posterior derivations are divided 
by the corresponding power spectra of the four anterior derivations, which results in four 
spectral ratios as a function of frequency (from 0 to 60 Hz).  The maximum value in the 
alpha frequency (8-14 Hz) band of each ratio is determined, and then the four maximal 
values are averaged to produce a single alpha ratio for the epoch.  Alpha ratios for all 
epochs for a subject are then averaged to produce a mean alpha ratio for the subject (Fig 
2C).  Applying this measure to the exploratory group, we find that the ASD population 
has a significantly lower mean peak alpha ratio (p ≤ 0.0034) than the control population, 
consistent with the visual inspection results (Fig 2A,B).  We note that the peak alpha 
ratios for EEG data recorded during sleep in the exploratory group showed little to no 
peak, and ASD and control values exhibited no significant differences.   
Spectral features in the second group of subjects – the validation group – remain much 
the same (Figure 2).   In the validation group, the ASD population’s mean peak alpha 
ratio is significantly below that of the control population (p ≤ 0.0025). We conclude that 
the significant spectral features identified in the first group of subjects are validated in the 
second group of subjects. 
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3.2 Functional network analysis reveals specific biomarkers of ASD. 
3.2.1 Network Density 
After inferring the functional networks from the EEG data (see Methods, 
Functional network inference and methods), we investigate differences in network 
topology between the ASD and control groups.  Many statistics exist to assess network 
structure [50,60];  here we focus on one of the most fundamental – the density – which is 
computed by summing the number of edges in a network, and then dividing by the 
number of possible edges. We note that, for the functional networks inferred here, a 
higher density value indicates an increased level of correlation within the network.  The 
mean density across epochs was calculated for each subject, and averaged within-group 
(Fig 3a).  In the training group, the ASD population produced a significantly lower mean 
density than that of the control population (p ≤ 0.028), consistent with some findings in 
the literature [53,55,77,111–115].  However, in the validation analysis, we found no 
significant difference in density between the two groups (p=0.502, Fig 3a).    
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Figure II.3. Network analysis reveals that select edges show a significantly diminished density in ASD versus 
control groups, though not in overall mean density.   
A. Mean density of ASD (blue, Asperger’s in green) and control (red) groups.  In the 
training data, the mean density of the ASD group was significantly lower than the mean 
density of the control group (p ≤ 0.028).  However, in the validation data no significant 
difference was found (p=0.50). Error bars represent two standard errors of the mean. 
B. In the training data, no significant difference in degree between ASD and control 
groups was found at any node location.   
C. The “edge mask”. Edges in the mean control network which were significantly greater 
than the surrogate control distribution are shown in red (n=23), while edges in the mean 
ASD network which were significantly lower than the surrogate ASD distribution are 
shown in blue (n=16). Seven edges (shown in orange) were found to distinguish both 
control from surrogate and ASD from surrogate, and were retrospectively used to form a 
mask of highly selective edges.   
D. The mask density reveals a significant difference between the ASD group and the 
control group in training data, as expected (p ≤ 0.0019).  The mask density of the ASD 
group was significantly lower than the mask density of the control group (p ≤ 0.0085) in 
the validation data as well.   
E. In a retrospective study, the intersection mask density was computed.  In both the 
training and validation data, the ASD intersection mask density was found to be 
significantly lower than the control intersection mask density (p ≤ 0.0163 in training data, 
p ≤ 0.0006 in validation data). 
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We also examined the mean density for EEG data recorded during NREM sleep in the 
exploratory group, but we detected very few edges (approximately 0.005 density) and 
found no significant difference between the mean ASD and control populations (p = 
0.4578). Finally, we also investigated the density in the correlation networks using 
alternative reference montages, including the transverse and Hjorth Laplacian [26] 
reference montages.  The results were similar to the double banana montage for the wake 
data (Supplementary Figure 1) and for the sleep data.  In addition to analysis of 
correlation networks, we also considered networks inferred using a frequency domain 
measure of linear association:  the coherence (see Methods).  We computed the density of 
these coherence networks for the exploratory group sleep and wake data using four 
reference montages (double banana, transverse, Hjorth Laplacian, and neck) at 4 
frequencies with 5 Hz bandwidth (centers at 3.5 Hz, 8.5 Hz, 13.5 Hz, and 18.5 Hz) and 8 
frequencies with 3 Hz bandwidth (centers at 2.5 Hz, 5.5 Hz, 8.5 Hz, 11.5 Hz, 14.5 Hz, 
17.5 Hz, 20.5 Hz, and 23.5 Hz).  Using the double banana montage on wake data, at 5 Hz 
bandwidth, the coherence densities were found to have no significant difference except at 
13.5 Hz (p = 0.0055). At 3 Hz bandwidth, the only significant difference between ASD 
and control was found at 14.5 Hz (p = 0.0312).  At this frequency the coherence density 
values were low (approximately 0.01), and further examination revealed that the 
significance was driven by two control subjects with high coherence values, thus this 
result was not considered reliable.  The coherence results were not examined further in 
this study.  
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In an effort to spatially localize the functional network differences between the ASD 
and control populations, we computed measures of localized density of different brain 
regions between groups.  To compute these measures we restricted the derivations used in 
our density calculation to a subset of the network corresponding to a specific region of 
the scalp, comparing the left and right hemispheres, and the anterior to posterior halves of 
the network. We found the ASD population mean density to be significantly lower than 
the control population mean density in the left hemisphere (p=0.036), right hemisphere 
(p=0.013), and near significance in the anterior hemisphere (p=0.073) and posterior 
hemisphere (p=0.058).  The left-right inter-hemispheric density (i.e., the density of 
connections between left and right hemispheres) difference was also nearly significant 
(p=0.058), but the anterior-posterior inter-hemispheric density (i.e., the density of 
connections between nodes in the anterior and posterior halves of the full network) was 
not found to differ significantly between the groups (p=0.954).  These results indicated 
that density differences were not localized to specific regions, but were distributed 
throughout the brain.  Because the overall change in density was not validated in the 
second data group, and because network degree analysis likewise did not indicate 
localization of differences in connectivity (see Network Degree below), we did not 
perform analysis of the density in specific brain regions in the validation population.  
 
3.2.2 Network Degree 
In an effort to spatially localize the functional network differences between the 
ASD and control populations, we computed a second statistic – the degree – which 
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measures the number of edges that contact a node.  In the training data (Fig 3b, top) we 
tested each node between ASD and control populations and found no significant 
differences when Bonferroni corrected (p > 0.0028 for all edges, where Bonferroni 
correction of p=0.05 for 18 comparisons is 0.05/18 = 0.0028), indicating no evidence for 
spatial organization of the difference in the node degree between the two groups.   
  
3.2.3 Mask Density 
We expect high variability in the functional networks inferred from each 2 s 
epoch, as the brain responds to evolving internal and external demands.  To establish 
more stable functional network representations, we computed the average functional 
network of each patient.  In practice, the average functional network is the mean of all 
functional networks inferred across time for a patient.  The average functional network is 
a weighted network, in which the edge weight indicates the proportion of times that edge 
appears in all epochs for a patient.  For example, an edge weight of 0 indicates that two 
pairs of sensors (i.e., derivations) are never correlated across all 2 s epochs, while an edge 
weight of 1 indicates two pairs of sensors that remain correlated in each 2 s epoch. We 
have recently shown that average functional networks computed for more than 100 s of 
data constitute stable network templates or “cores” [98,100].  These template networks 
computed for the ASD and control subjects reveal heterogeneous network structures 
within each group, rather than a common difference visually distinguishing each ASD 
subject from each control subject (Fig 4A). We then computed the mean of these 
template networks across subjects within each group, resulting in the mean ASD template 
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network, and the mean control template network (Fig 4B).  The mean ASD and control 
template networks displayed grossly similar structures, with slight differences in specific 
edge weights difficult to discern from visual inspection alone. 
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Figure II.4. Sample mean networks for the ASD and control subjects exhibit variability, and the mean group 
networks exhibit qualitatively similar patterns.  
A. Example networks from 5 ASD subjects (top row, blue) and 5 control subjects (bottom 
row, red) are shown to demonstrate how individual subjects varied in their mean network 
edge weights.  While some edges were consistently more represented (as in the frontal 
area, for example), individual subjects did not exhibit identical network weight patterns 
across the group.   
B. Mean group networks for ASD (top row, blue) and control (bottom row, red) appear to 
have superficially similar patterns of edge weights. 
 
We next considered whether these template networks facilitate the development of an 
additional biomarker of ASD.  To do so, we investigated specific edge weights. To 
identify those edges that differed most significantly between the ASD and control 
subjects, we generated surrogate network data.   Briefly, we generated these surrogate 
data under the null hypothesis of no difference between the ASD and control populations 
(see Methods, Bootstrap test for significantly different edges).    We find in the mean 
ASD template network 16 edges with significantly lower weights than in the surrogate 
ASD distribution (p ≤ 10-5), and two edges with significantly greater weights than in the 
ASD surrogate distribution (p ≤ 10-5).  Conversely, we find in the control population 23 
edges with significantly higher weights than in the surrogate control distribution (p ≤10-
5), and only one edge with significantly lower weight than in the surrogate control 
distribution (p ≤ 10-5).  Using the 16 edges from the ASD population significantly lower 
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than their surrogate distribution and the 23 edges from the control population 
significantly higher than their surrogate distribution we constructed an edge mask (Fig 
3C), representing a candidate subset of edges to distinguish the ASD and control groups. 
If these edges are truly selective, then analysis focused only on these edges should 
improve the distinguishability of the ASD and control populations beyond a global 
network density measure that includes all edges. 
 
Table II.2. Edges chosen for “mask”.  
ASD edges were significantly below the surrogate ASD bootstrap distribution, and 
control edges were significantly above the surrogate control bootstrap distribution. 
ASD mask 
network 
edges 
Fp1-F3/Fp1-F7;  F3-C3/F7-T3;  C3-P3/C4-P4;  C3-P3/T3-T5;  P3-O1/P4-O2;  
P3-O1/T5-O1;  F4-C4/F8-T4;  F4-C4/T4-T6;  C4-P4/P4-O2;  C4-P4/T4-T6;  
C4-P4/T6-O2;  C4-P4/Cz-Pz;  P4-O2/T5-O1;  P4-O2/T6-O2;  T5-O1/T6-O2;  
T4-T6/Cz-Pz 
Control mask 
network 
edges 
Fp1-F3/Fp2-F4;  Fp1-F3/Fp1-F7;  Fp1-F3/F7-T3;  Fp1-F3/Fp2-F8;  Fp1-F3/F8-
T4;  F3-C3/F7-T3;  F3-C3/T3-T5;  F3-C3/Fp2-F8;  C3-P3/T3-T5;  P3-O1/T5-
O1;  Fp2-F4/Fp1-F7;  Fp2-F4/F7-T3;  Fp2-F4/Fp2-F8;  Fp2-F4/F8-T4;  F4-
C4/C4-P4;  C4-P4/T4-T6;  C4-P4/Cz-Pz;  P4-O2/T6-O2;  Fp1-F7/F7-T3;  Fp1-
F7/Fp2-F8;  Fp1-F7/F8-T4;  F7-T3/Fp2-F8;  Fp2-F8/F8-T4 
Edges 
common to 
both masks 
Fp1-F3/Fp1-F7;  F3-C3/F7-T3;  C3-P3/T3-T5;  P3-O1/T5-O1;  C4-P4/T4-T6;  
C4-P4/Cz-Pz;  P4-O2/T6-O2;   
 
 
To quantify this in a summary statistic, we computed the proportion of edges in 
the edge mask for each network in all subjects and both populations.  The result is a 
single statistic for each network, which we call the mask density.  For each subject, we 
compute the average mask density across all 2 s epochs. In the training analysis, we find 
a significantly higher mask density in the control group versus the ASD group (p ≤ 
0.0019, Fig 3D).  We then applied the same edge mask – deduced from the training data - 
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to the validation data.  Here, we again find that the mask density is significantly higher in 
the control networks compared to the ASD networks (p ≤ 0.0085, Fig 3D).  In this case, 
the connectivity strength of a subset of edges serves as a robust biomarker of ASD. 
 
3.3 Post-hoc measures 
To further explore features of the population data, we performed the following 
eight analyses after validation of the two biomarkers. 
 
3.3.1 Classification Model 
We performed a quadratic discriminant analysis (QDA) classification with the 
two validated biomarkers.  Using the peak alpha ratio and the mask density, we trained a 
QDA classifier on the training group of subjects (excluding Asperger’s subjects), and 
then tested this classifier on the validation group of subjects (excluding Asperger’s 
subjects).  The QDA classifier successfully classified ASD subjects with 83% sensitivity 
(10/12 correctly classified as ASD) and 68% specificity (21/31 subjects correctly 
classified as control, Fig 5).    
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Figure II.5. Discriminant analysis classifies the ASD and control groups. 
A. Scatter plots of the quadratic discriminant analysis (QDA) using the two validated 
measures of peak alpha ratio and mask density.  Classification rate was 83% sensitivity 
and 68% specificity. For classification purposes, Asperger’s subjects were excluded.  The 
quadratic classification curve (magenta) was trained on the training data population (top) 
and used to classify the validation data population (bottom). 
C. The validated measures for all patients (both the training and validation groups), and 
including the Asperger’s subjects (green circles), displayed here for visualization.  Visual 
inspection suggests a difference between ASD and control populations, and that 
Asperger’s subjects are removed from the main cluster of ASD subjects.  
 
3.3.2 Edge Mask 
The mask used in the initial classification was a union of edges from the ASD 
mean network that were significantly less than surrogate distribution, and edges from the 
control mean network that were significantly greater than surrogate distribution.  There 
were seven edges that were common to these two groups, which we call the intersection 
mask.  To investigate whether this intersection mask better discriminated the ASD and 
control groups, we performed a post-hoc calculation of this intersection mask density 
(using only the seven edges identified) and classification analysis similar to that 
described above, but now using the intersection mask.  Consistent with the results 
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reported above, we find a significantly higher intersection mask density in the control 
group versus the ASD group in the training data (p ≤ 0.0163, Fig 3E) and in the 
validation data (p ≤ 0.0006, Fig 3E). Using the peak alpha ratio and the intersection mask 
density, we then trained a QDA classifier on the training group of subjects, and then 
tested this classifier on the validation group of subjects.  The QDA classifier performed 
similarly to the classification with the union mask, and successfully classified ASD 
subjects with 83% accuracy and 64.5% specificity. 
 
3.3.3 Gender 
ASD is known to be more common in males than females [116–118]. We 
performed post-hoc analysis of male versus female subjects using control subject data 
only, and found no difference in density or mask density.  For the spectral analysis, there 
was a significantly higher peak alpha ratio found for male subjects compared to female 
subjects in the training group (20.46 versus 8.38, p=0.039), such that the peak alpha ratio 
in neurotypical females was closer to ASD values; the peak alpha ratio was also greater 
in males compared to females in the validation group, however this difference was not 
significant (14.33 versus 14.10, p=0.3792).   
 
3.3.4 Asperger’s Syndrome 
Five of our ASD subjects met criteria for Asperger’s syndrome (a less severe 
form of ASD [119]), three from the exploratory population and two from the validation 
population.  When evaluated separately, we found that the results for the Asperger’s 
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subjects were either between the ASD-only and the control subject averages or outlying 
to both overall populations (see green markers in Figures 2,3,5).  For the exploratory 
population, the alpha ratio was 5.5 for ASD subjects excluding Asperger’s subjects, 6.2 
for Asperger’s subjects, and 15.2 for control subjects; while mean density was 0.034 for 
ASD subjects excluding Asperger’s subjects, 0.039 for Asperger’s subjects, and 0.046 for 
control subjects; the mask density was 0.10 for ASD subjects excluding Asperger’s 
subjects, 0.14 for Asperger’s subjects, and 0.18 for control subjects.  For the validation 
population, the alpha ratio was 4.31 for ASD subjects without Asperger’s subjects, 24.40 
for Asperger’s subjects, and 14.20 for control subjects, while mean density was 0.037 for 
ASD subjects without Asperger’s subjects, 0.099 for Asperger’s subjects, and 0.041 for 
control subjects, and mask density was 0.113 for ASD subjects without Asperger’s 
subjects, 0.320 for Asperger’s subjects, and 0.160 for control subjects.  Inclusion or 
exclusion of the Asperger’s subjects in the ASD group altered the p-values reported 
above, did not affect the significance of the results reported. These observations for a 
small group (five) of Asperger’s subjects suggest further study from a larger population is 
warranted.  
 
3.3.5 Data stability 
In the exploratory group we examined the effects of differences of number of 
epochs, number of subjects in each population, and differences in number of subjects at 
each age for the density and peak alpha ratio.  We compared ASD and control 
populations using the first 100 epochs, the last 100 epochs, 100 randomly selected 
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epochs, and in all cases found the ASD density to be consistently significantly lower than 
control population mean density.  We also repeated this same analysis using only 13 
control subjects (to equal the number of ASD subjects), randomly selected 100 times, and 
in each case found changes in density and peak alpha ratio consistent with the previous 
analysis.  Finally, we repeated the analysis above, but first averaged subjects within each 
age group, and then across the age groups, and found results consistent with the previous 
analysis, both for density and for peak alpha ratio.   
 
3.3.6 Effects of the presence of sleep 
To evaluate whether sleep, or lack thereof, impacted group differences on the 
wake EEG, we conducted a post-hoc analysis of the two validated biomarkers (alpha ratio 
and mask score) for all subjects (exploratory and validation) who slept versus those who 
did not sleep during the EEG recording session.  We found no significant differences 
within the ASD and control groups. Between groups (ASD versus control) for the “sleep” 
and “did-not-sleep” conditions, we found that the validated results persisted. In addition, 
we note that maximum power in the alpha band of the 4 posterior electrode deviations 
was significantly higher in the ASD subjects compared to the control subjects, whether 
subjects who did not sleep were included (p=0.0015) or excluded (p=0.033) from the 
analysis. These results do not provide evidence that the presence of sleep during the EEG 
recording session affected the alpha band findings.  We note that these results are 
consistent with our previous findings that stable functional networks in the EEG persist 
across different states of consciousness [98].  
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3.3.7 Addressing high frequency myogenic artifact contamination 
Electromyogram (EMG) contamination has been shown to impact the EEG at all 
frequencies [110], particularly in the beta frequency range (i.e. 14-30 Hz) and above.  To 
evaluate for possible EMG contamination, we calculated the validated mask score 
measure for all subjects with data bandpass filtered between 1-10 Hz. We found that the 
mask score remained significantly different between groups (p=0.0016), indicating that 
this network biomarker was not driven by myogenic artifact.”  
 
3.3.8 Addressing low frequency myogenic artifact contamination 
An important concern in the analysis of scalp EEG data is the presence of muscle 
artifact.  To assess the impact of muscle artifact, we computed the slope of the 
logarithmic power versus logarithmic frequency in the four frontal electrode deviations.  
For normal neuronal population activity, this slope is known to be approximately -2 (e.g., 
[He, Zempel, et al, Neuron, 2010] [120]). The effect of broadband muscle artifact is to 
increase this slope, i.e., to “flatten” the power spectrum. Computing this slope for the 
exploratory population from 1-15 Hz (e.g., including low frequencies through the alpha 
band), we find that for each subject and frontal electrode, the slope ranges between [-3, -
1.7] in ASD subjects, and [-3.3, -1.5] in control subjects. These slope values are 
consistent with neuronal activity not dominated by muscle artifact.  Moreover, we find no 
significant differences in the slope between the two groups at any of the four frontal 
electrodes.  These results support the conclusions that muscle artifacts are not dominant 
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in the lower frequency band (1-15 Hz), and that the impact of muscle artifact is similar in 
the ASD and control groups. 
 
3.3.9 Application of the weighted phase-lag index produces similar density results 
To investigate how an alternate method of coupling analysis impacts the results, 
we reanalyzed the combined data using the Weighted Phase-Lag Index (WPLI) [121].  
We chose this measure because of its utility for minimizing the effects of volume 
conduction [121]. We focused the WPLI analysis on the alpha frequency range (8-12 
Hz), motivated by the spectral analysis results and the requirement of a relatively narrow 
frequency interval for a meaningful calculation of phase.  Using this alternate measure, 
we found that the validated mask score remained significantly different (p=0.036) 
between groups (see Supplementary Figure 2).  
 
3.3.10 Distribution of ASD severity on validated biomarkers 
The distribution of ASD severity (see Methods, Subjects and EEG recordings) 
with regard to the validated biomarkers was also examined. This preliminary analysis - 
for a limited number of subjects - suggests that the severity of ASD symptoms is 
correlated with the proposed biomarkers (see Supplementary Figure 3).  However, future 
studies utilizing data collected systematically to assess ASD severity are required to 
further assess the significance of this relationship. 
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4. Discussion 
In this manuscript, we described an approach to find and validate 
electrophysiological biomarkers for the quantitative identification and characterization of 
autism in children.  Using a validation group, we confirmed two hypotheses: the peak 
alpha ratio is lower in ASD than control subjects, and the connectivity strength of a select 
group of edges is lower in ASD than control subjects.  We also performed a discriminant 
analysis using the training group to train the classifier, and the validation group to test the 
classifier, using our two validated hypothesized measures: the peak alpha ratio and the 
mask density, and found that the classifier was able to successfully identify ASD subjects 
in the validation data with 83% accuracy and control subjects with 68% accuracy.   These 
results suggest that specific and robust electrophysiological biomarkers of ASD exist, and 
may provide an additional tool for quantitative diagnosis of ASD. 
Spectral features of ASD. Recent EEG studies on the brain rhythms that 
distinguish ASD from control subjects have produced conflicting reports, in terms of 
power, brain location, and frequency, including results in the alpha frequency band 
[41,53,80,113,114,122–125].  Changes in brain rhythms associated with ASD remain an 
active area of research, and understanding the reasons for differences in the reported 
changes remains a challenge.  Analysis of subtle disorders such as ASD using brain 
imaging is known to be confounded by many artifacts [126].  Different results in the 
reported literature may be due to differences in task, subject population demographics, 
choice of EEG reference [26], or methodology.  Low statistical power in EEG studies, 
caused by too few subjects, may also impact the reported results [126,127].  Moreover, 
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the broad category of ASD may include subject populations with qualitatively different 
neurophysiology, and therefore result in the study of qualitatively different phenomenon.  
The consequent difficulties of comparing results across studies highlights the utility of 
studies with high subject numbers and within study validation of hypotheses.   
In this study, using data from both an exploratory dataset group and validation test 
group obtained during unconstrained states, we found no significant differences in mean 
power in any frequency band between ASD and control groups. However, we show that 
the peak alpha ratio, which represents the anterior-posterior alpha gradient, is 
significantly lower in the ASD group than the control group, in both the training and 
validation populations.   
Higher frontal power and lower posterior power has also been observed in relation 
to higher behavioral inhibition and lower sociability [92].  While this measure has not 
been directly related to ASD, abnormal social interactions is one of the main behavioral 
traits used to diagnose autism [38].  In addition, a higher alpha gradient is observed in the 
behavioral state of quiet wakefulness and with brain maturation [128]. Our findings may 
reflect immaturity in cortical rhythms or the decreased ability of ASD patients to generate 
this behavioral state. The reproducibility and significance of the changes in alpha band 
activity reported here suggest this measure may serve as a reliable biomarker of ASD. 
Future studies including detailed behavioral assessments are needed to determine if 
alterations in this cortical measure correlate with specific behavioral symptoms.  
Network features of ASD. Much recent work has focused on the inference and 
analysis of network structure in ASD [129,130].  Typically, this work has analyzed the 
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anatomical connections (i.e., the “structural network”) between brain regions. The 
analysis of “functional networks” inferred from scalp EEG data of ASD subjects is 
relatively sparse ([114,125,131,132] for example).  Functional networks are presumed to 
reveal the transient patterns in communication between brain regions [59].  Because ASD 
has been postulated to be a disorder of communication between various brain regions, 
analysis of functional networks is a natural choice. The most frequently reported finding 
has been lower widespread network connectivity, and occasionally higher local 
connectivity in specific locations (EEG: [77,111,112,123], fMRI: [53,55,122], MEG: 
[113,115]).  However, contradictory findings have also been reported (EEG: 
[73,81,82,84], fMRI: [32,125], MEG: [113], Other/Multiple modalities: [114,133,134]).  
Specifically, recent work has reported higher long range connectivity in ASD subjects 
(fMRI: [80,83], Other/Multiple modalities: [114]). Connecting EEG network findings to 
behavior and pathology remains an active research challenge. To that end, lower long-
range connectivity in ASD has been related to clinical symptoms such as reduced 
capacity to integrate brain areas needed for task performance and socialization, while 
higher local connectivity has been related to an increased focus on specific tasks that is 
seen in the obsession with repetitive behaviors (fMRI: [54,135] MEG: [115]).  However, 
further research is required to establish definitive relationships between alterations in 
EEG functional networks and specific behavioral profiles.   
In the exploratory phase of our study, we found that overall connectivity, as 
measured by the density of functional networks inferred using the cross correlation was 
significantly lower in the ASD group than the control group, consistent with reported 
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results in the literature.  However, this finding was not reproduced in a subsequent 
validation study, highlighting the uncertainty of the initial results.  Although we carefully 
selected patients and EEG segments for analysis, potential explanations for this lack of 
validation include the considerable measurement noise inherent in EEG, the diversity of 
characteristics inherent in ASD, and the choice of coupling analysis parameters. A 
measure of density that targets specific edges revealed significantly lower connectivity in 
the ASD subjects that was confirmed in the validation study. We therefore hypothesize 
that the proposed spatially focused analysis is a more sensitive measure, potentially 
omitting non-relevant brain activity that may obfuscate the differences between the 
subject groups. 
An EEG classifier for ASD.  A primary goal of this work was to use the scalp 
EEG to propose a biomarker for ASD.  Using a common quadratic discriminant analysis, 
trained on the training group of subjects and tested on the validation group, but excluding 
Asperger’s subjects we classified 83% of ASD subjects and 68% of control subjects 
correctly.  There have been few previous attempts to classify ASD subjects based on 
EEG data [44,77,131,136].  Combined with existing diagnosis procedures, a biomarker 
deduced from scalp EEG would provide an additional cost-effective and relatively 
straightforward procedure to improve ASD diagnosis.  Ultimately, a deep understanding 
of ASD will require insight into the biological and neurological mechanisms of the 
disease. However, new biomarkers may immediately help clinicians both diagnosis ASD 
and assess the severity.  Although we did not consider severity of ASD symptoms in the 
analysis, we did find a broad range of deduced measure values within the ASD 
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population.  In the peak alpha ratio and selected edge subset weight there was 
considerable variation within groups.  Moreover, we note that the ASD subjects 
diagnosed with Asperger’s syndrome tended to have peak alpha ratios and mask density 
values closer to the mean control group values than the mean ASD group values (Figure 
5). This indicates the possibility that the proposed biomarkers, and perhaps others, could 
be parametrically related to the severity of ASD symptoms.  To further test the 
relationship between metrics inferred from electrophysiological data and disease severity 
remains a topic of continuing study.  A complete understanding of this relationship would 
benefit from additional clinical diagnosis relating quantitative measurements to severity 
of behavior and behavioral test scores, behavioral analysis that includes the control 
population, and more specific behavioral tasks during recording.  
 
5. Conclusions   
The field of quantitative analysis of brain activity through spectral and network 
analysis is a promising one.  Recently, more research has focused on the application of 
these tools to electrophysiological signals for characterization of ASD [114]. In this 
work, we separated two large subject pools for the exploration of hypotheses and the 
subsequent validation of these hypotheses with a completely naïve testing population.  
This study has the benefit of a large subject pool, and represents one of very few EEG 
studies conducted on children with ASD, when the condition still has the best possible 
prognosis for amelioration [43].  We also used principled methods to mitigate the impact 
of common challenges in EEG research, including the effects of volume conduction and 
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reference effects.  However this study was limited by a lack of recorded severity scale of 
ASD or socio-behavioral analysis for all subjects, which might relate the level of the 
proposed biomarkers to the severity of the symptoms.  In addition, the clinical data 
consisted of spontaneous behavior, which means that no task was performed, and subject 
movement was not stringently controlled. This lack of behavioral constraint invariably 
adds noise to the data, but also has the potential benefit of making the results more 
widely applicable in clinical use.  We evaluated clinical EEGs obtained under 
standardized recording settings for all subjects.  However, it is possible that differences in 
vigilance between ASD and control groups could affect the findings. Finally, we note that 
subjects diagnosed with Asperger’s disease were not removed from the analysis, which 
introduces an additional variability into the ASD subject population.  
In general, brain imaging research in ASD suffers from many significant sources 
of potential discrepancy and ambiguity, so it becomes essential for studies to be 
conducted with high numbers of subjects and within study validation. In particular, 
because different convergent causes (genetically or neuro-anatomically) may result in 
similar behavioral outcomes, establishing a specific relationship between imaging or 
biological metrics with behavioral diagnostic tests that measure severity of ASD 
symptoms, from the most severely affected and through the normal population [137,138], 
may provide new insights.  Efforts to standardize the development of diagnostic testing in 
psychiatry are already underway, as performed by Arfken et al [139,140], who use EEG 
findings from the literature to present a systematic approach for standardizing biomarkers 
into clinically useful diagnostic screens; a similar approach could potentially be applied 
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here.  This study represents a step in the direction of finding neuroimaging metrics that 
clinicians may use to diagnose ASD, and potentially measure severity and decide on 
proper treatment approach.   
We have demonstrated two biomarkers, an alpha frequency power measure and a 
subset of edges, that significantly differentiate between a population of ASD and control 
subjects, and which were validated within study.  Although these population indicators do 
not provide a definitive diagnosis of ASD, they do provide complementary quantitative 
tools for clinicians to supplement existing diagnosis criteria. Moreover, these results 
further support the utility of quantitative EEG analysis in the diagnosis of ASD. 
 
.
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CHAPTER III. ANALYSIS OF SCALP EEG DATA RECORDED FROM 
PATIENTS WITH ASD DURING SLEEP 
1. INTRODUCTION 
Analysis of brain activity in health and disease during sleep is an important 
complement to investigations of the awake brain, and in addition there are several 
advantages that sleep data provide when compared to wake data; during sleep, the subject 
is not engaging in active cognition, the impact of external sensory information is reduced, 
and artifacts – like muscle movements – are reduced. Previous research also suggests that 
ASD subjects show marked differences from control subjects in sleep [32–36]. However, 
in Chapter II we saw that although two validated biomarkers for ASD occur in the wake 
state, preliminary results did not find significant differences in the stage-2 sleep data 
when analyzing coherence, cross-correlational network density, or spectral power. It is 
possible that the absence of similar findings in sleep is due to important functional 
differences that are present in ASD subjects while awake, and that the biomarkers we 
measured reflect these differences.  However, a different feature set may elucidate a 
hitherto concealed difference between the two groups during sleep.   
The entire dataset on which the study in Chapter II was based included not only 
wake and stage-2 sleep data, but also stage-1 sleep and stage-3 sleep data.  These are all 
known as stages of non rapid-eye-movement sleep. Stage-1 sleep is known as drowsiness 
or pre-sleep, stage-2 sleep is the predominant sleep during a normal night’s sleep, and 
stage-3 sleep is usually grouped with stage-4 sleep as ‘slow wave sleep’, ‘delta sleep’, or 
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deep sleep. In this chapter we further examine the ASD biomarkers during these two 
additional sleep states, and analyze new biomarkers for all wake and sleep states.   
As is common with cognitive disorders, ASD is often comorbid with other 
disorders, such as epilepsy [141].  The data used in our study has been specifically 
selected by a board-certified neurologist (Dr. Catherine Chu, MGH) to exclude subjects 
with epilepsy.  However, some research has found that even when epilepsy is not present, 
subjects with ASD may present similar features such as high voltage amplitude activity 
[142,143]. To examine this possibility, in addition to the previously considered measures 
of network density and spectral power, we add several new measures to the analysis.  We 
also examine inter-hemispheric and anteroposterior connectivity, an index of 
interhemispheric symmetry known as the brain symmetry index (BSI), and several time 
domain features commonly used in seizure detection, and which reflect characteristics 
such as high voltage amplitude and noise in data.  These features are the zero-crossing 
rate (ZC), which has been considered to be a simple and easy measure of signal noise 
[37]; the number of local maxima and minima (MM), which should reflect the level of 
oscillations in the signal; the line length (LL), which is the summation of the distance 
between each consecutive data point, also known as the total variation of the signal; and 
the root mean squared amplitude (RMSA), which measures the average amplitude of the 
voltage trace in an epoch.  
We find no significant differences using any of these features for any of the sleep 
states, nor for the wake data, except for the two biomarkers we had already determined 
(masked network density and the alpha ratio, see Chapter II). There were specific 
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instances of significance, particular to metrics at specific derivations for particular 
conditions, but we concluded that these results were spurious due to the large number of 
statistical comparisons, and further examination of the datasets in these cases.  While no 
new biomarkers for ASD were found, we interpret these negative results, both clinically 
and scientifically, and propose how these results are informative to ASD research.  
 
2. METHODS 
This research was conducted on the same dataset utilized in Chapter II, with the 
inclusion of data from additional sleep conditions. Identical preprocessing and feature 
analysis was conducted, with the inclusion of several new measures.  For details 
involving subject preparation, data preprocessing, and analysis methods, see the Methods 
section of Chapter II.  Although the methodology of deriving the new features is 
described in Chapter IV, it is also included here for completeness.  In what follows, each 
feature was examined as a mean over all derivations, and also at each individual 
derivation.   
 
2.1 Additional analytical measures  
 To investigate possible differences in interhemispheric and anteroposterior 
connectivity, we calculated two additional terms from the network edge values.  We first 
selected those edges that comprised connections between the left and right hemisphere, 
and between the anterior and posterior half of the brain, and then calculated network 
	  	  
65 
density on these subsets of electrodes by summing the total number of edges over the 
total number possible edges within the electrode subset.  
 
2.1.1 Brain Symmetry Index (BSI) 
The brain symmetry index is a measure of interhemispheric symmetry, originally 
calculated using power spectral density.  It is calculated as the absolute value of the 
relative interhemispheric difference in power spectral density, as given by the mean of 
eight left-right symmetric bipolar EEG derivations [144]. It is defined as 
1)          𝐵𝑆𝐼 𝑡 =    1𝑀𝑁/2 𝑄!"(𝑡)!/!!!!!!!!  
 
where Qik(t) is given by  
 
2)          𝑄!" 𝑡 =    𝑅!" 𝑡 − 𝐿!"(𝑡)𝑅!" 𝑡 + 𝐿!"(𝑡)  
with N being the number of bipolar channels (16 in this case, not including the two center 
derivations), and M the number of frequencies analyzed. The power spectral density for 
the bipolar channel Si(t) within a frequency band k and centered at time t is given by 
Rik(t) and Lik(t) for the right and left sides of the electrode configuration, respectively 
[144].  
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2.1.2 Time domain measures 
 Several of the most successful features for the detection of seizures were 
identified from the seizure detection research [144–148], and calculated as described 
below. For all measures presented below, the data were first re-referenced to a bipolar 
montage and band pass filtered from 0.5-25 Hz, as described in Chapter II. Each measure 
was applied to the data in each epoch and derivation, and then average over derivations 
and epochs for each patient. 
 
2.1.3 Zero Crossings  
 The number of zero crossings in the EEG has been thought to change during 
seizure activity, possibly related to changes in frequency, but perhaps more robust to 
artifacts than frequency domain measures [144,147,148]. The number of zero crossings 
for each derivation in each epoch is calculated here as the sum of all zero crossings of the 
zero-mean EEG data within the epoch. A zero crossing is defined as occurring when 
x(k)<0 and x(k+1)>0 or x(k)>0 and x(k+1)<0, where x is the EEG value for each sample 
k, and x(k) and x(k+1) denote consecutive data points in the voltage trace. This is 
accomplished in MATLAB using the function dsp.ZeroCrossingDetector.m 
 
2.1.4 Local Maxima and Minima  
The number of local maxima and minima in the EEG was proposed in [144,148] 
to be one of the most successful features for detecting seizures.  It is defined as the sum 
of the number of local maxima and minima within each epoch.  We calculate these 
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quantities using the MATLAB function findpeaks.m, which detects maxima, applied to 
the epoch’s voltage trace, as well as on an inverted voltage trace, to find both the maxima 
and the minima of each voltage trace.  
 
2.1.5 Line Length  
Line Length, also known as curve length was first introduced by Olsen et al. 
[149], and subsequently proposed by Esteller et al. and Greene et al. [146,148] as an 
efficient feature for detecting the onset of seizures. It is calculated according to the 
equation below, and implemented using the function diff.m in MATLAB applied to the 
voltage trace in each epoch, and then taking the absolute value and summing.  
 
3)          𝐿 = 𝑎𝑏𝑠[𝑥 𝑘 −   𝑥 𝑘 − 1 ]!"!!!  
 
where Ns is the number of data points in an epoch, and x is the EEG value for each 
sample k.  
 
2.1.6 RMSA 
Root mean squared amplitude (RMSA) is one of the most widely used tools for 
the detection and diagnosis of seizures in the neonatal intensive care units [148,150–152]. 
RMSA was calculated for each epoch, and each derivation, according to the following 
equation: 
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4)          𝐴 = 1𝑁𝑠 𝑥! 𝑘!"!!!  
 
where Ns is the number of data points in an epoch, and x is the EEG value for each 
sample k.  
 
3. RESULTS 
In Chapter II, we showed that one of the two robust biomarkers for ASD found in 
the wake data was the masked network density.  That is, the density of a subset of edges 
in the entire network of EEG derivations, selected for their ability to discriminate 
between ASD and control.  We hypothesized that the same selection of edges would 
provide a distinction in functional network density between the ASD and control subjects 
during sleep. However, neither the overall density nor either of the two identified masked 
densities revealed a significant difference between the ASD and control subjects during 
sleep (Fig III.1). Interestingly, the patients diagnosed with Asperger’s syndrome (green 
dots in Figure III.1), appear closer to the values of the control subjects, for this and other 
metrics.  However, even when excluding the patients with Asperger’s syndrome form the 
analysis, the metrics of ASD and control groups overlap. It is of some interest that the 
application of the edge-selection mask does reduce the mean ASD density values in 
relation to mean control density values for all sleep states, however this difference did not 
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reach significance.  
  
Figure III.1. Density and Masked Density values do 
not distinguish between ASD and Control during 
sleep 
Total network density (top), network density 
using the union of highly selective edges 
from Chapter II (middle), and network 
density using the intersection of highly 
selective edges from Chapter II (bottom) are 
shown with ASD in blue and control in red. 
Mean density values are expressed by the 
bars, while individual dataset values are 
represented as black dots overlaid on the 
bars.  Subjects with Asperger’s syndrome 
instead of ASD are represented by green 
dots. Error bars (gray) indicate twice the 
standard error of the mean. Bars on the left 
are from wake data, which were divided into 
two data set to provide a training and testing 
set of data; see Chapter II. Data from N1, 
N2, and N3 sleep states are on the right, 
with increasingly dark bars to distinguish 
sleep states. While masked ASD and control 
densities are significantly different for wake 
data, they are not significantly different for 
the  sleep data.  
 
Similar to the binary network density results, the weighted network density (Fig 2, top) 
does not show any significant differences between the ASD and control groups in any 
sleep state, nor in wake.  Left-right interhemispheric density results are similar to the 
overall density , which indicates a distributed network connectivity over the brain in these 
measures, and no specific differences between the left and right hemispheres. Anterior-
posterior densities show no significant differences between ASD and control during 
sleep, and have similar mean values and large variance (Fig 2, bottom). These functional 
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networks results again provide no additional biomarkers to distinguish ASD from control 
patients during sleep. 
 
 
Figure III.2. Weighted Density and Inter-
hemispheric Density features do not distinguish 
between ASD and control during sleep 
Weighted network densities (top), left-right 
interhemispheric densities (middle), and 
anterior-posterior network densities 
(bottom) are shown for each group. Bars 
represent feature means (blue for IS, red for 
control), individual datasets are overlaid by 
black dots with patients with Asperger’s 
syndrome in green, and grey confidence bars 
indicate two standard errors of the mean. 
Left-right interhemispheric density results 
are similar to overall density.   
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Figure III.3. Frequency Domain Features do not 
distinguish ASD from control patients during sleep. 
Alpha ratio (top), Delta frequency power (2-
4 Hz, second from top), theta frequency 
power (5-8 Hz, middle), alpha frequency 
power (9-13 Hz, s econd from bottom), and 
beta frequency power (14-20 Hz, bottom) 
are shown.  Bars represent feature means 
(blue for IS, red for control), individual 
datasets are overlaid by black dots with 
patients with Asperger’s in green, and grey 
confidence bars indicate two standard errors 
of the mean. Alpha ratio shows significant 
differences during the wake state, as shown 
in Chapter II, but not in the sleep states. The 
power density in individual frequency bands 
does not show significant differences 
between the ASD and control groups during 
sleep.
  
 
As discussed in Chapter II, the alpha ratio is significantly lower in the ASD than control 
subjects, in both exploratory and validation wake datasets. However, there is no significant 
difference in alpha ratio between the ASD and control groups during sleep.  This is not surprising, 
since the occipital posterior peak that forms a component of the alpha ratio is largely present 
during wakefulness, not sleep. Power in the delta, theta, alpha, and beta frequency bands (see 
Chapter II) show no difference between the ASD and control groups for any state, at any 
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frequency.  We note that stage-3 sleep has the highest levels of delta power, as well as theta 
power, as expected [89]. 
 
 
 
Figure III.4. Time Domain Features reveal no significant differences between ASD and control groups. During 
wake or sleep. 
Zero-crossing rate (A), number of local maxima and minima per epoch (B), line length (C), and 
RMSA (D) show no significant differences between ASD and control in wake or sleep. Bars 
represent feature means (blue for IS, red for control), individual datasets are overlaid by black 
dots, patients with Asperger’s syndrome in green, and grey confidence bars indicate two standard 
errors of the mean. Zero-crossing rate decreases with sleep state, while RMSA increases with 
sleep state.   
 
The lack of significant differences between the ASD and control groups continued 
with the time-domain features. No significant differences were found during wake or any 
sleep stage in the zero-crossing rate (Fig 4, top), local maxima and minima (Fig 4, 2nd 
from top), line length (Fig 4, 2nd from bottom), and RMSA (Fig 4, bottom).  Zero-
crossing rate is negatively correlated with depth of sleep, which is expected as deep sleep 
is dominated by larger amplitude, slow wave activity, and thus fewer oscillations, or zero 
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crossings.  Interestingly this pattern is not seen as strongly with local maxima and 
minima.  RMSA, however, does reflect the increase in voltage amplitude in deeper sleep.  
 
 
 
Figure III.5. Brain Symmetry Index for power density at delta, theta, alpha, beta frequencies does not differ 
significantly between the ASD and control patients. 
Delta power BSI (A), Theta power BSI (B), alpha power BSI (C), and beta power BSI (D) show 
no significant differences between ASD and control in wake or sleep.  Bars represent feature 
means (blue for ASD, red for control), individual datasets are overlaid by black dots with patients 
with Asperger’s syndrome in green, and grey confidence bars indicate two standard errors of the 
mean.  
 
Finally, the brain symmetry index also does not show any significant differences 
between the ASD and control groups. However, both the ASD and control groups 
demonstrate significant hemispheric asymmetry over all frequency bands examined 
during stage-1 sleep, compared to other sleep or wake states. This differs from the small 
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differences in interhemispheric connectivity shown in Figure 2. However, we note that 
asymmetry in spectral power does not indicate a lack of connectivity.  
 In addition to these analyses each feature was examined at each derivation 
separately, and also while accounting for the effects of age using a linear model and an 
associated statistical test, but when accounting for multiple comparisons and data 
variability again no significant differences were found (data not shown). 
 
4. DISCUSSION 
We find no significant differences between the ASD and control groups in any of 
the measures applied during any of the sleep stages examined (stage-1, stage-2, or stage-
3).  This is particularly surprising for stage-1 sleep for the two biomarkers found in 
Chapter II, as stage-1 sleep is the closest in brain activity to wake, and thus would seem 
to be likely to share similar EEG characteristics. These results suggest that EEG data 
recorded during sleep does not distinguish ASD from control subjects.  
There are two interpretations of these results, and reasons for the lack of 
significant differences observed.  First, these results suggest that, at the very least, ASD is 
a subtle disorder. It is possible that the electrophysiological features reflecting the 
neurological underpinnings of ASD may take a great deal of statistical power and high 
temporal and spatial resolution, along with carefully constructed tasks, to discern with 
confidence. These results call into question the EEG features associated with ASD; some 
EEG features may be epiphenomena related some behavioral aspect of ASD subjects 
while awake, such as greater motion, and not indicative of underlying neurology. Second, 
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it is possible that ASD is currently measureable in the brain only through differences in 
active, wakeful function and not when the brain is at rest, and that it is truly a disorder of 
the function and not the structure of the brain.  
We showed that features commonly used in seizure detection (e.g., the time 
domain measures) found no discernable difference between the ASD and control groups. 
This result suggests that, for the group of ASD and control children selected for this 
study, the EEG does not present seizure-like dynamics (e.g., large amplitude voltage 
oscillations) or other signs of epilepsy detected by these measures that distinguish the two 
groups.  
 
5. CONCLUSIONS 
None of the network, spectral, or time domain features chosen found significant 
differences between ASD and control groups in stage-1, stage-2, or stage-3 sleep, 
including the validated biomarkers of masked network density and alpha ratio determined 
in Chapter II.  In addition, no biomarkers beyond those already examined in Chapter II 
showed any significant differences between ASD and control in wake states. Few studies 
have been reported on the EEG features of ASD subjects during sleep. One reason may 
be the lack of significant findings. We conclude that diagnosis and study of the EEG 
characteristics of ASD may best be performed on wake subjects.  
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CHAPTER IV. INFANTILE SPASMS CHARACTERIZED BY EEG CORTICAL 
VOLTAGE OSCILLATIONS 
1. INTRODUCTION 
Infantile Spasms (IS) is a rare, but malignant, age-dependent epileptic syndrome 
causing devastating developmental delays. It is separated into symptomatic, cryptogenic, 
and idiopathic subtypes.  Symptomatic infantile spasms comprise approximately 75% of 
cases and are secondary to a known neurological disorder (for example tuberous 
sclerosis). Cryptogenic IS indicates a suspected but not conclusively identified 
neurological disorder.  Idiopathic signifies that no disorder has been identified.  Disease 
prognosis is poor for all subtypes, particularly for symptomatic IS, unless the epilepsy 
can be controlled. However, the optimal methods to treat and control this disease remain 
unknown.  This study focuses on characterizing cryptogenic IS by its cortical voltage 
oscillations.   
Infantile spasms are currently characterized by the triad of myoclonic or tonic 
seizures, electrophysiological features such as background hypsarrhythmia and ictal 
electrodecrement, and mental retardation.  Onset is always before 12 months of age and 
peaks between 4 and 7 months [23]. The most characteristic electrophysiological feature 
is a large amplitude, chaotic background voltage known as hypsarrhythmia, named from 
hypselos, a Greek word for “high”. There is great variability in the electrophysiological 
abnormalities associated with IS, including a number of different types and 
characteristics of hypsarrhythmia [23,153]. Moreover, hypsarrhythmia is not always a 
reliable indicator of IS, as some cases have been found without this activity, though the 
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voltage output in those cases is large amplitude. The spasms themselves are usually 
subtle in appearance, and often difficult for parents to recognize as a serious problem. 
They appear as brief head nods with quick extension and flexion of the torso, arms, and 
legs, generally appearing in groups and during transitions between wake and sleep. 
During the spasms the ictal EEG is also quite variable, though it is most commonly 
associated with an electrodecrement, or sudden suppression of EEG activity lasting for 
several seconds [153,154]. Fast activity and high-voltage spikes, or polyspikes, and slow 
waves may also be present throughout the EEG.  
Hypsarrhythmia is suspected to be a cause for poor cognitive outcome, and good 
prognosis has been related to faster background activity (<75% delta), lower total levels 
of hypsarrhythmia, and absence of electrodecremental discharges [22,23,155–157]. It is 
thought that the hypsarrhythmia and lack of organized background EEG patterns may 
interfere with the ability of the brain to behave in an orderly manner, and a relationship 
between poor cognitive outcome has been found with poor epilepsy outcome [158].  
Despite these prominent characteristics, hypsarrhythmia assessment exhibits poor 
inter-rater reliability, which has been identified as a threat to clinical trial validity [8].  As 
such, there is need for a quantitative method of characterizing IS that might serve as an 
aid to clinical diagnosis, and eventually also give information as to severity, and 
potentially specific characteristics related to subtype, phenotype, or prognosis.  In 
particular, it is desirable that such a methodology is applicable to the noisy, low-
resolution, and natural state recordings of clinical EEG data, during which controlled  
subject behavior and structured experimental conditions or tasks are not possible. 
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Methods developed applicable to this scenario extends use to a larger number of clinics, 
in particular those where expertise on such rare conditions such as IS is not available. 
Infantile spasms may present very differently between different subjects and at different 
times, particularly if ictal events are recorded or not, so it is essential to measure features 
robust enough to reflect the presence and severity of IS under as varied conditions as 
possible.  Many promising sources of quantitative measures exist, including those that 
give information about functional network connectivity, frequency domain features, and 
time domain features. Because of the connection between hypsarrhythmia and prognosis, 
and its prominence, it is a natural target for potential features.  In addition, extensive 
research is being conducted on features for use in automatic detection of seizures, which 
may serve to detect EEG features in infantile spasms as well.  
In this study, we apply ten features from functional network, spectral, and time 
domain analyses to IS and control patient populations between 2-16 months.  We show 
that these measures successfully distinguish the two patient groups. We identify 
redundant information expressed by these features, and use show that a subset of features 
utilized in a linear determinant classifier distinguishes between IS and control groups. 
These results provide a quantitative tool to assess hypsarrhythmia from standard clinical 
EEG recordings. This procedure defines a tool to aid clinical diagnosis of this devastating 
disease.  
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2. METHODS 
2.1 Subjects and EEG recordings 
 EEG recordings from 22 subjects, ages 2 months to 16 months (mean 8 months), 
diagnosed with cryptogenic IS were obtained from the Epilepsy Phenome/Genome 
Project (EPGP).  From these subjects, 13 EEG recordings were made while awake, and 
16 during sleep.  
For control data, 105 subjects age 2 months to 16 months (mean 7.8 months) with 
normal EEG recordings (as defined by clinical electroencephalographers independent 
from this study) were retrospectively identified from recordings performed at 
Massachusetts General Hospital between 2/1/2002 and 4/1/2011. Clinical chart review 
was performed and only those children with documented nor- mal neurodevelopment and 
non-epileptic events without known EEG characteristics were included in the control 
group for analysis. For the control subjects, no medications were taken at the time of 
EEG recording.  Recordings included 32 acquired during wake and 95 during sleep. 
Recordings included electrooculogram (two channels), scalp EEG (19 Ag/AgCl 
electrodes placed according to the 10–20 international system: FP2, F4, C4, P4, O2, F8, 
T4, T6, Fz, Cz, Pz, Fp1, F3, C3, P3, O1, F7, T3, and T5) and electrocardiogram using a 
standard clinical recording system (Xltek, a subsidiary of Natus Medical).  In an effort to 
maximize the number of usable cryptogenic IS datasets while keeping data consistent, 
only the twelve electrodes common to all subjects were analyzed: Fp1, Fp2, F3, F4, F7, 
F8, C3, C4, P3, P4, O1, O2.  Signals were sampled at 200, 256, 500 or 512 Hz and stored 
on a local server. Analysis of the data from these subjects was performed retrospectively 
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under protocols approved and monitored by the local Institutional Review Boards 
according to the National Institutes of Health guidelines.  
All EEG recordings were manually reviewed by an experienced 
electroencephalographer (C.J.C.) and large movements and muscle artifact  
removed. Wake and non-rapid eye movement (NREM) sleep intervals were identified by 
visual analysis as per standard criteria [89]. Only patients with at least 50 s of artifact-free 
EEG data were included in the analysis [98].  
 
2.2 Data preprocessing for time-domain, frequency-domain, and network analysis. 
For time domain and network analysis, the EEG data were filtered with a 3rd 
order Butterworth, zero-phase filter (high pass at 0.5 Hz to avoid slow drift, and low pass 
at 25 Hz to avoid higher-frequency line noise harmonics). Because the EEG data were 
selected to avoid large movements and muscle artifact, noncontiguous points occurred in 
some of the datasets; we removed 0.5 s from both sides of each noncontiguous point 
before further analysis. Visual analysis and a simulation study (not shown) confirmed 
that this removal was sufficient to mitigate artifacts produced at the noncontiguous points 
during the filtering process [159]. For frequency-domain analysis, the EEG data were not 
filtered, but 0.5 s was removed from each noncontiguous point to maintain consistency 
with the time-domain and network analysis.  
In order to optimize near-field activity and reduce electrical contamination from 
the physical reference, both filtered and non-filtered data were re-referenced according to 
a longitudinal bipolar montage, leaving 10 bipolar signals (‘derivations’) in place of the 
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original 12 electrode signals. This reference montage was chosen due to utilize all 
electrodes available for the entire cohort of subjects.  The resulting derivations consisted 
of: Fp1-F7, Fp1-F3, F3-C3, C3-P3, P3-O1, Fp2-F8, Fp2-F4, F4-C4, C4-P4, and P4-O2. 
Bipolar montages are considered one of the best available options to improve spatial 
resolution in EEG with a limited number of electrodes [26].  
All EEG data were then divided into non-overlapping windows of 1 s duration 
(windows containing concatenated data from noncontiguous time points were discarded). 
We use 1 s intervals to approximately maintain stationarity in the time series (which 
requires short epochs) while keeping sufficient data for accurate coupling estimates 
(which requires long epochs) [98,159]. Finally, we normalized the data from each 
derivation within each window to have zero mean. All data preprocessing and subsequent 
analysis were performed using custom software developed in MATLAB.  
 
2.3 Frequency domain measures  
For the spectral analysis of the unfiltered data, the power spectrum for each 1 s 
epoch was computed using the multitaper method implemented in the Chronux toolbox 
[91], with 1 taper, a time-bandwidth product of 1, and a frequency resolution of 1 Hz. 
Frequencies below 0.5 Hz were omitted to avoid low-frequency drift in the data. For each 
subject this resulted in a power spectrum for each of the 10 re-referenced signals, for each 
1 s epoch. To characterize the power spectra for each patient we then averaged the power 
spectra across all epochs. We call this non-normalized power spectrum the absolute 
spectral power.  To characterize differences between the IS and control groups in the 
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distribution of power over frequency bands, i.e. in the shape of the power spectrum, 
rather than absolute power values, we calculated the relative spectral power.   This was 
calculated by summing the power over the frequencies within a band and dividing that by 
the total summed power over all frequencies.  In other words, it is the proportion of the 
total power contained within any particular frequency band.  
 
2.4 Functional network inference and measures  
As previously noted in Chapter II there are many approaches to determining 
functional connectivity from time series data [94], including multiple coupling measures 
(e.g., linear or non-linear) and different strategies for determining network edges, and we 
selected a simple measure of linear coupling: the cross correlation. The cross correlation 
is a bivariate measure of linear association between two brain regions, and serves as a 
basic measure of electrocortical functional connectivity [61,95]. As mentioned in Chapter 
II, most linear and nonlinear measures appear to perform equally well on simulated and 
observed macroscopic brain voltage data [96,97]. As in Chapter II, to examine functional 
network connectivity we calculated both statistically thresholded binary network 
densities, and weighted network densities using the maximum cross-correlation value.  
Each subject possessed at least 50, 1 s epochs of data (min 56, max 2132, mean 
536), which is sufficient to support stable functional network representations [98–100]. 
To create functional networks, we follow the procedure outlined in [101] and applied in 
[98–100,159]. For each patient, we create a functional network for each 1 s epoch of 
filtered data using the 10 derivations (signals) of data, based on the cross correlation of 
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the data between each pair of derivations. We note that each signal in each 1 s interval is 
standardized to zero mean and unit variance before performing the correlation analysis. 
Doing so reduces the differences in amplitude between signals and mitigates a potential 
confounding factor in the correlation analysis [102]. We use the maximum absolute value 
of the cross correlation over time lags of ±250 ms to measure the coupling (which 
encompasses the duration of known neurophysiological processes and cross-cortical 
conduction times [104,105]). To construct the weighted network, each edge is set equal to 
the maximum absolute value of the cross correlation. We note that this value ranges 
between 0 and 1.  Averaging these weights over all edges results in a weighted network 
density for that epoch.   
To calculate the binary network densities, we first assess the variability of the 
cross correlations across lags, by computing the average variance of the cross correlations 
between all derivation pairs for each 1 s epoch of a subject; this provides a common 
measure of variability that we apply to assess the significance of each cross correlation 
statistic [101]. For each 1 s epoch, an undirected binary functional network is inferred 
from these correlations based on their significance. In these binary networks, an edge 
value of 1 represents a statistically significant correlation between the two derivations, 
and an edge value of 0 indicates a weaker correlation. To correct for the multiple 
significance tests within each 1 s epoch, we use a linear step-up procedure controlling the 
false detection rate (FDR) with q = 0.05. For this choice of q, 5% of the network 
connections are expected to be falsely declared [106]. This procedure results in a 
thresholding of the significance tests of the correlation — not of the correlation value 
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itself — for each 1 s epoch [101]. The networks obtained in this manner have an 
associated measure of uncertainty, which is the expected number of edges incorrectly 
declared present.  
To mitigate the impact of volume conduction [26,95] on the functional network 
analysis, we identified the correlations deemed significant at zero lag, and removed these 
edges from the analysis for both the weighted and binary network density. In doing so, 
we expect to remove both spurious correlations due to volume conduction and true 
correlations that occur at zero lag; in this sense, this procedure is conservative. This 
approach has an added benefit of reducing the effect of montage selection, whereby 
subtraction of signals may result in spurious coupling between derivations that share 
electrodes.  
 To assess the network structure, the binary density for each network is calculated 
in the standard way as the number of edges detected (at non-zero lag) divided by the total 
number of possible edges (45 minus the number of spurious edges detected at zero lag) 
[60]. To compute the weighted network density, we average the weights over all edges.  
The mean binary or weighted density for each subject is calculated as the average density 
across all epochs for the subject. The mean density for each group (IS and control) is 
calculated as the mean of the subject densities within each group.  
 
2.5 Time domain measures 
 To capture aspects of the amplitude variation, background complexity, and 
multifocal spikes described in the hypsarrhythmia EEG, we applied a variety of well-
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described time domain measures. Several of the most successful features for the detection 
of seizures were identified from seizure detection research [144–148], and though our 
data is structurally different, the same features were considered due to the possibility that 
they may also give useful information, and calculated as described below. For all 
measures presented below, the data were first re-referenced to a bipolar montage and 
bandpass filtered from 0.5-25 Hz, as described above. Each measure was applied to the 
data in each epoch and derivation, and then average over derivations and epochs for each 
patient. 
 
2.5.1 Zero Crossings  
 The number of zero crossings in the EEG has been thought to change during 
seizure activity, possibly related to changes in frequency, but perhaps more robust to 
artifacts than frequency domain measures [144,147,148]. The number of zero crossings 
for each derivation in each epoch is calculated here as the sum of all zero crossings of the 
zero-mean EEG data within that epoch. A zero crossing is defined as occurring when 
x(k)<0 and x(k+1)>0 or x(k)>0 and x(k+1)<0, where x is the EEG value for each sample 
k, and x(k) and x(k+1) denote consecutive data points in the voltage trace. This is 
accomplished in MATLAB using the function dsp.ZeroCrossingDetector.m.  
 
2.5.2 Local Maxima and Minima  
The number of local maxima and minima in the EEG was found by van Putten et 
al. and Greene et al. [144,148] to be one of the most successful features for detecting 
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abnormal oscillations at seizure onset.  It is defined as the sum of the number of local 
maxima and minima for each epoch.  We calculate these quantities using the MATLAB 
function findpeaks.m, which detects maxima, applied to the epoch’s voltage trace, as well 
as on an inverted voltage trace, to find both the maxima and the minima of each voltage 
trace.  
 
2.5.3 Line Length  
Line Length, also known as curve length was first introduced by Olsen et al. 
[149], and subsequently proposed by Esteller et al. and Greene et al. [146,148] as an 
efficient feature for quantifying background complexity, such as variations in frequency 
content or spike density. It is calculated according to the equation below, and 
implemented using the function diff.m in MATLAB applied to the voltage trace in each 
epoch, and then taking the absolute value and summing.  
 
1)          𝐿 = 𝑎𝑏𝑠[𝑥 𝑘 −   𝑥 𝑘 − 1 ]!"!!!  
 
where Ns is the number of data points in an epoch, and x is the EEG value for each 
sample k.  
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2.5.4 RMSA 
Root mean squared amplitude (RMSA) can be used as an estimate of feature 
known as the cerebral function monitor, one of the most widely used tools for the 
detection and diagnosis of seizures in the neonatal ICU [148,150–152]. Here we applied 
this metric to capture variations in amplitude described in hypsarrhythmia. RMSA was 
calculated for each epoch, and each derivation, according to the following equation: 
 
2)          𝐴 = 1𝑁𝑠 𝑥! 𝑘!"!!!  
 
where Ns is the number of data points in an epoch, and x is the EEG value for each 
sample k.  
 
2.6 Linear regression controlling for age 
In order to control for age, and account for the effect of condition in terms of 
main and interaction effects, we first constructed a linear regression model for each 
metric using only age as an explanatory variable. We then created a full model using age, 
the test condition (a categorical variable representing either IS or control), and an 
interaction term. The p value of an F-statistic was calculated to test the model using just 
age as a predictor (null model) against the full model.  The F-statistic was calculated  as 
the difference in deviance between the two models, divided by the squared dispersion, 
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and the resulting p-value was calculated from the cumulative distribution function of the 
F-distribution.  
 
2.7 Feature cross-correlation 
To investigate to what extent the ten features represent redundant information, we 
computed the zero-lag cross-correlation for each pair of features across patients. We note 
that, before this computation, each feature was first averaged for each patient across 
electrode derivations and epochs.  
 
2.8 Classification of datasets  
We performed a linear discriminant analysis to examine how well the features 
classify the IS and control populations. To do so, we used the MATLAB function 
‘classify’, selecting the classification option ‘linear’; in this method, a discriminant 
function fits a multivariate normal density to each group, with covariance estimates 
stratified by group. We used a 10-fold cross-validation method to assess the performance 
of the classification. With this type of cross validation, the data is divided into 10 distinct 
and non-overlapping subsets of 90% used for training data and 10% used for test data. 
This is repeated for all datasets, and the average result reported.  The performance of this 
test has been proposed to be the most similar to the performance that would be produced 
on newly collected validation dataset [160]. In addition, we performed a principal 
component analysis to test how well the data could be separated using a lower number of 
dimensions. A 10-fold cross-validation was used to assess the performance of a linear 
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discriminant analysis using just the two primary components.  Finally, a 10-fold cross-
validation was used to assess the performance of a linear discriminant analysis using just 
two of the most distinct features, RMSA and weighted network density, and delta PS and 
weighted network density.  
 
3. RESULTS 
In this section, we describe the application of network, spectral, and time-domain 
analysis to the EEG data recorded from IS and control subjects. We propose candidate 
biomarkers from each analysis category motivated by traditional quantitative EEG 
analysis techniques, seizure detection, and measures with potential to highlight 
electrophysiological characteristics in patients with infantile spasms, specifically 
hypsarrhythmia.  Below we briefly describe the measures tested.  We note that for each 
subject the biomarkers are calculated for every electrode derivation within non-
overlapping 1 s epochs, after re-referencing to a bipolar montage and after filtering 
between 0.5-25 Hz.   
To examine functional network connectivity, we calculated both statistically 
thresholded binary network densities and weighted network densities using the maximum 
cross-correlation value.  To examine frequency band activity, we performed a power 
spectral analysis at each canonical frequency band up to 20 Hz: delta (2-4 Hz), theta (5-8 
Hz), alpha (9-13 Hz), and beta (14-20 Hz).  We did not examine higher frequencies due 
to possible contamination from muscle and motion artifacts [110].  We also examined 
several time domain measures: the number of zero crossings of the mean-subtracted 
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voltage trace (ZC); the number of local maxima and minima (MM); the line length (LL), 
also known as the total variation of the signal; and the root mean squared amplitude of 
the voltage trace (RMSA).  These measures have either been previously found to 
correlate with seizures or proposed to capture features of  the amount of hypsarrhythmic 
activity occurring in a subject [144–146,148].   
We first examined all measures at each derivation over the scalp topology, both to 
identify the spatial distribution of measures within subjects and more importantly to 
determine whether differences between IS and control groups were isolated to specific 
regions or distributed throughout the scalp.  Within each group small but consistent 
differences in some measures were found between the front and back of the scalp, but not 
between the left and right of the scalp (see Supplementary Material). In addition, a 
feature found to correlate strongly with unilateral epileptiform discharges or focal 
seizures, the “Brain Symmetry Index” [144] did not reveal any significant left-right 
asymmetry in IS during wake or sleep.  Despite the front to back differences observed 
within each group, we found no evidence for spatial differences between the IS and 
control groups (i.e., if a measure was significantly larger in IS than control in one 
derivation, it was so for all derivations; see Supplementary Materials). We thus conclude 
that measure differences between IS and control are spatially distributed, not focal. 
Therefore, to simplify subsequent analysis,  we reduce the number of features under 
consideration without losing substantial information by averaging each measure over all 
derivations.  
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In addition to the dramatic neurological evolution that normally occur during 
development [161], IS has been found to change with patient age, generally disappearing 
by 5 years of age [162].  It is therefore important to account for age as a confound in the 
analysis as age-related changes may obscure differences between the IS and control 
groups. To address this, for each measure we constructed a linear regression model 
controlling for age. The model included the effects of group, age, and interaction between 
the two, so that independent significant differences between groups could be determined 
(see Methods). As we show below, age does have a significant impact on some features 
(See Supplementary Material), yet significant differences remain in the feature values 
between the IS and control conditions.  All significance results are presented in below, 
and plots illustrating how the measures change with age are included in the 
Supplementary Materials. 
 
3.1 Functional network analyses reveal significant but conflicting differences. 
Epilepsy is increasingly studied from the perspective of its effects on the 
functional connectivity of the brain, an approach that has yielded valuable information on 
the state of the brain as well as seizure onset, propagation, termination [29,163,164]. Due 
to the low number of derivations in our EEG recordings (10, from 12 electrodes) and the 
distributed nature of the features, we focus our functional network analysis on density, a 
summary statistic of network structure.  The density is computed by summing the number 
of edges in a binary network or the edge weights in a weighted network, and then 
dividing by the maximum number of possible edges [165].  For the functional networks 
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derived here, a higher density indicates an increased level of correlation in the scalp EEG. 
For each subject, we calculated the density for each epoch, averaged a patient’s results 
across epochs, and then averaged across patients within-group (Fig 1, see Methods: 
Network analysis procedure).   
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Figure. IV.1 Network analysis reveals significant differences in IS versus control density  
A Mean density of IS (blue, individual subjects shown as black dots) and control (red) 
groups during wake. The mean density of the IS group was significantly lower than the 
mean density of the control group (p≤0.013, and p≤0.0015 after controlling for age, and 
accounting for effective condition in terms of main and interaction effects, using a linear 
regression analysis, plots in supplementary materials). Error bars represent two standard 
errors of the mean (95% confidence interval). B Mean density of IS and control groups 
during sleep. The mean density of the IS group was significantly higher than the mean 
density of the control group (p≤1.2x10-6, and p≤5.5x10-6 after accounting for age). C 
Mean density calculated from maximum cross-correlations of IS and control groups 
during wake. The mean density of the IS group was significantly higher than the mean 
density of the control group (p≤2.7x10-5, and p≤6.3x10-5 after accounting for age).  D 
Mean density calculated from maximum cross-correlations of IS and control groups 
during sleep. The mean density of the IS group was significantly higher than the mean 
density of the control group (p≤3.7x10-10, and p≤1.2x10-9 after accounting for age). 
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Table IV.1: Network Density during wake and sleep for IS and control groups.  
The p-values associated with the difference in means (third column) are calculated using a t-test. 
The p-value of the difference while accounting for age are computed using a linear modeling 
approach.  
 IS Control p-value p-value with  age 
Wake Bin 0.009 0.018 p≤0.013 p≤0.002 
W Weight 0.534 0.493 p≤2.7x10-5 p≤6.3x10-5 
Sleep Bin 0.007 0.003 p≤1.2x10-6 p≤5.5x10-6 
S Weight 0.558 0.523 p≤3.7x10-10 p≤1.2x10-9 
 
In both wake and sleep we found that the weighted density was significantly 
greater in IS than in control, although the difference was small (Fig 1, Table 1, p-values 
calculated using a t-test). This significance persisted between the groups when accounting 
for age.  By contrast, while binary density was significantly different between the IS and 
control groups during both wake and sleep, the mean value for IS was lower in control 
during wake (Fig 1, Table 1). We note that the binary density values are extremely low, 
near 0.01, indicating sparse networks.  Therefore, the density values are more sensitive to 
the inclusion or exclusion of small number of edges (i.e., if only a single edge were 
detected for all epochs of a subject, the inclusion of one additional edge would double the 
density). We are therefore cautious in interpreting the significance of the binary network 
results. 
The significance of a higher weighted network density in the IS group is not 
immediately clear.  Hypsarrhythmia, the most significant feature of IS, is characterized 
by erratic and chaotic voltage traces. We would not expect such disorganized activity to 
manifest as increased functional network connectivity as found in the weighted network 
results, particularly as correlations at zero-lag have been removed. However this result 
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corresponds with previous research that IS subjects demonstrated higher coherence in all 
frequency bands than control [166]. An alternative possibility is that the increased density 
values in the IS group reflect another EEG feature with increased coupling over the scalp 
(e.g., the electro-decrement periods, transitions from hypsarrhythmia to electro-
decrement, or another characteristic). We note that, in what follows, we will show that 
the changes found for the weighted density are consistent with results computed using 
other measures.  
 
3.2 Frequency domain analyses reveal a significant difference at canonical frequency 
bands, particularly delta frequency (2-4 Hz). 
Rhythmic activity is one of the most important and commonly studied features of 
scalp EEG. Changes in rhythms often correlate with changes in cognitive state, as well as 
changes due to disease [27]. To assess rhythmic activity in the EEG data, we computed 
the power spectra from 1 s epochs, and averaged these power with each canonical 
frequency bands (Fig. 2, also see Methods: Frequency domain analysis procedure). In 
both wake and sleep, the power in IS is significantly greater than control for every 
frequency band (Table 2).  These results hold when accounting for age, with the 
exception of beta frequency power during wake. 
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Table IV.2: Power in canonical frequency bands during wake and sleep for IS and control groups.  
The p-values associated with the difference in means (third column) are calculated using 
a t-test. The p-value of the difference while accounting for age are computed using a 
modeling approach.  
 IS 
Mean 
Control 
Mean 
p-value p-value with 
age 
Wake Delta 165.09 35.44 1.3x10-9 1.7x10-7 
Wake Theta 29.98 6.77 1.9x10-4 3.6x10-3 
Wake Alpha 4.29 1.12 1.2x10-6 6.6x10-5 
Wake Beta 1.38 0.74 0.005 0.078 
Sleep Delta 150.11 49.76 3.3x10-15 3.9x10-14 
Sleep Theta 23.39 7.29 1.0x10-11 2.8x10-11 
Sleep Alpha 3.88 1.62 2.5x10-8 1.3x10-7 
Sleep Beta 1.12 0.57 2.9x10-5 1.4x10-4 
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Figure IV.2 Spectral Analysis at canonical frequency bands reveals significantly different absolute power in IS 
versus control groups.  
A WAKE Mean Absolute Spectral Power of IS (blue, individual subjects shown as black 
dots) and control (red) groups at canonical frequency bands. From left to right frequency 
bands are Delta (2-4 Hz), Theta (5-8 Hz), Alpha (9-13 Hz), and Beta (14-20 Hz).  The 
mean density of the IS group was significantly higher than the mean density of the 
control group at all frequency bands (Delta: p≤1.3x10-9, and p≤1.7x10-7 after controlling 
for age, Theta: p≤1.9x10-4, and p≤3.6x10-3 after controlling for age, Alpha: p≤1.2x10-6, 
and p≤6.6x10-5 after controlling for age, Beta: p≤0.005, and p≤0.078 after controlling for 
age, not significant). Error bars represent two standard errors of the mean (95% 
confidence interval). Note that mean group values diminish by almost a factor of 10 
between each frequency band. B N2 SLEEP Mean density of IS (blue, individual subjects 
shown as black dots) and control (red) groups. From left  to right frequency bands are 
again Delta (2-4 Hz), Theta (5-8 Hz), Alpha (9-13 Hz), and Beta (14-20 Hz).  The mean 
density of the IS group was again significantly higher than the mean density of the 
control group at all frequency bands (Delta: p≤3.3x10-15, and p≤3.9x10-14 after 
controlling for age, Theta: p≤1.0x10-11, and p≤2.8x10-11 after controlling for age, Alpha: 
p≤2.5x10-8, and p≤1.3x10-7 after controlling for age, Beta: p≤2.9x10-5, and p≤1.4x10-4 
after controlling for age). Error bars represent two standard errors of the mean (95% 
confidence interval). 
 
 
Greater activity in the delta and theta frequency bands is a characteristic of 
hypsarrhythmia [31,166], and our findings that IS subjects have higher power than the 
control subjects are consistent with this result.  The increase in power in IS patients 
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compared to control subjects in both wake and sleep (where muscle artifacts are less of a 
concern) is seen across all frequency bands, though at each increasing frequency band 
absolute power diminishes by a factor of approximately ten. We propose from these 
results that hypsarrhythmia influences brain activity across all frequency bands, though 
the dominant effect remains at lower frequency. This may be expected, as large, rapid 
changes in voltage produce changes in power across many frequency bands. We note 
that, at each frequency, IS power values show a visibly greater variance across subjects 
than the control power values (Fig. 2).  If hypsarrhythmia is indeed a major contributor to 
the difference in power, the variability to which it is present in each subject, and in 
different recording sessions, may explain the increased variance in the IS population.  
 
3.3 Time domain analyses reveal significant differences between the IS and control 
groups. 
We computed four time domain measures already utilized in seizure detection 
research, but not yet associated with the characteristics of hypsarrhythmia. These 
measures are: the number of Zero Crossings (ZC), the number of local maxima and 
minima (MM), the line length (LL), and the root mean square ratio (RMSA) (Fig 3, also 
see Methods: Time domain analysis). We note that infantile spasms do not display 
characteristics associated with other types of seizures; instead, patients with IS present an 
electrodecrement during seizure, rather than large amplitude voltage activity, and 
persistent hypsarrhythmia that appears throughout the inter-ictal state. We propose that 
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time domain measures designed to detect large variations in voltage behavior between the 
ictal and inter-ictal state will reflect differences in IS as well.   
 
Table IV.3: Time domain features during wake and sleep for IS and control groups.  
The p-values associated with the difference in means (third column) are calculated using 
a t-test. The p-value of the difference while accounting for age are computed using a 
modeling approach.  
 IS Mean Control 
Mean 
p-value p-value with 
age 
Wake ZC 8.8645 11.1136 p≤0.0027 p≤0.0035 
Wake MM 22.3275 28.0224 p≤2.2x10-5 p≤0.00025 
Wake LL 690.6727 388.3601 p≤4.1x10-7 p≤3.3x10-5 
Wake RMSA 33.1080 14.8291 p≤9.8x10-12 p≤9.6x10-10 
Sleep ZC 7.2632 8.7346 p≤3.8x10-7 p≤2.3x10-7 
Sleep MM 19.3926 23.0108 p≤2.8x10-6 p≤6.0x10-7 
Sleep LL 569.6053 398.0177 p≤9.3x10-7 p≤3.6x10-6 
Sleep RMSA 30.9998 18.4156 p≤1.1x10-12 p≤1.0x10-11 
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Figure. IV.3 Analysis of metrics derived from voltage traces reveals significant differences in IS versus control 
groups. 
A Mean number of zero crossings for IS (blue, individual subjects shown as black dots) 
are significantly lower than for the control group (red) during wake (p≤0.0027, and 
p≤0.0035 after controlling for age).  B Mean number of local and maxima and minima 
for IS (blue, individual subjects shown as black dots) are significantly lower than for the 
control group (red) during wake (p≤2.2x10-5, and p≤0.00025 after controlling for age).  C 
Mean Line Length (total variance of the signal) for IS (blue, individual subjects shown as 
black dots) are significantly higher than for the control group (red) during wake 
(p≤4.1x10-7, and p≤3.3x10-5 after controlling for age).  D Mean number of zero crossings 
for IS (blue, individual subjects shown as black dots) are significantly lower than for the 
control group (red) during wake (p≤9.8x10-12, and p≤9.6x10-10 after controlling for age).   
Analysis of sleep revealed a similar pattern as for wake.  
E Mean number of zero crossings for IS (blue, individual subjects shown as black dots) 
are significantly lower than for the control group (red) during sleep. (p≤3.8x10-7, and 
p≤2.3x10-7 after controlling for age).  F Mean number of local and maxima and minima 
for IS (blue, individual subjects shown as black dots) are significantly lower than for the 
control group (red) during sleep (p≤2.8x10-6, and p≤6.0x10-7 after controlling for age).  G 
Mean Line Length (total variance of the signal) for IS (blue, individual subjects shown as 
black dots) are significantly higher than for the control group (red) during sleep 
(p≤9.3x10-7, and p≤3.6x10-6 after controlling for age).  H Mean number of zero crossings 
for IS (blue, individual subjects shown as black dots) are significantly lower than for the 
control group (red) during wake (p≤1.1x10-12, and p≤1.0x10-11 after controlling for age).   
 
As with the spectral analysis, we find similar results for the time domain measures 
during wake and sleep; in both wake and sleep, all four metrics possess significant 
differences between the IS and control groups. This result persists when accounting for 
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age (see Table 3).  Zero crossings and local maxima and minima were lower in IS than 
control, while line length and RMSA were greater in IS than control.  
Line length and RMSA measure similar properties, reflecting the amplitude of the 
voltage trace. It is therefore not surprising that these two measures behave similarly for 
the data considered here, and are consistent with the effect of the large amplitude delta-
frequency activity characteristic of hypsarrhythmia [31,166]. Zero crossings and local 
maxima and minima have been interpreted as features representing the noisiness, or 
temporal complexity of a signal [37].  It is therefore reasonable that these two measures 
exhibit similar relationships between IS and control.  It is possible that as features of 
complexity, zero crossings and local maxima and minima reflect the presence of 
hypsarrhythmia in the IS subjects.  As previously stated hypsarrhythmia is characterized 
by large amplitude activity, especially at lower frequency. Such low frequency rhythms 
are often associated with reduced complexity of neural signals when compared to higher 
frequency rhythms [27].  A reduction in zero crossings and local maxima and minima 
may therefore reflect the increased power of the slower frequency activity.  If that is the 
case, we would expect a trend across subjects showing an inverse relationship between 
zero-crossings or local maxima and minima versus metrics of the slow, large amplitude 
voltage fluctuations, such as RMSA or line length or delta power. We explore these 
relationships between measures in the next section. We note that zero crossings and local 
maxima and minima may reflect another aspect of temporal complexity in the signal, 
perhaps the periods of electrodecrement.  
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3.4 Analysis of measure variance across subjects show significant differences for some in 
both states, in others only in sleep 
In the previous sections, we compared the mean value across patients of each 
metric between groups. However, as noted above, the variance of the metrics may also 
differ between the two groups; visual inspection of Figures 2 and 3 suggests increased 
variance of measures calculated for the IS group, compared to the control group.  The 
contrast between Hypsarrhythmia and electrodecrement periods, or variance simply due 
to the chaotic nature of hypsarrhythmia, could potentially lead to consistent differences 
between IS and control patients.  
 
 
Table IV.4: Variances of all features measured over epochs within subjects, during wake and sleep for IS and 
control groups.  
The p-values associated with the difference in variances (third column) are calculated 
using a t-test. The p-value of the difference while accounting for age are computed using 
a modeling approach.  
 IS Mean Contr Mean p-val p-val w age 
WAKE Vars     
Weight Net 0.0032 0.0030 0.36 0.33 
Delta 1.13x105 8.7x104 0.73 0.95 
Theta 6.01x103 8.95x103 0.83 0.87 
Alpha 98.05 629.8 0.59 0.88 
Beta 8.81 54.78 0.56 0.86 
ZC 12.48 20.01 0.022 0.1 
MM 28.49 33.86 0.062 0.22 
LL 6.12x104 2.72x104 6.1x10-4 0.015 
RMSA 224.7 85.08 1.1x10-4 0.0048 
RMSA/ZC 45.702 7.194 4x10-8 1.1x10-6 
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SLEEP Vars     
Weight Net 0.0033 0.0022 5.2x10-12 6x10-11 
Delta 1.39x105 1.04x104 1.3x10-16 2x10-15 
Theta 4.14x103 1.90x102 4.3x10-11 3.3x10-13 
Alpha 136.8 29.0 3.2x10-5 1.1x10-4 
Beta 15.63 9.71 0.31 0.48 
ZC 7.05 10.31 9.1x10-16 4.8x10-4 
MM 23.51 23.0 0.77 0.94 
LL 7.28x104 1.86x104 8.7x10-11 8.6x10-10 
RMSA 249.81 47.55 6x10-21 NA 
RMSA/ZC 86.921 8.860 9.8x10-21 NA 
 
For each subject we computed the variance of each feature across epochs 
separately at each of the ten derivations and then averaged the variances over the 
derivations.  We found that variance of the weighted network density and power spectra 
were significantly higher in IS than control in sleep, but no significant difference during 
wake. Zero crossings had significantly lower variance in IS than control in sleep, but not 
significantly different in wake after controlling for age.  Surprisingly local maxima and 
minima were not significantly different in variance in either state.  Line length and 
RMSA were significantly greater in variance in IS than control in both states however.  It 
is possible that the greater variances in line length and RMSA reflect the chaotic nature 
of hypsarrhythmia, which occurs in both wake and sleep states.  A greater variance in 
weighted network density during sleep but not wake is driven by the change in control 
variance, not IS.  This could reflect a change of cognitive state in control that is not 
present in IS. Greater variance in power spectra in IS during sleep but not wake could 
also reflect different cognitive states in control, however outliers in variance limit the 
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interpretation of this result. Ultimately the variance of a feature within a subject over time 
does not seem to be as robust an electrophysiological feature as the feature itself, and 
none were used in classification.  
However, it was apparent that features calculated for each epoch in individual IS 
and control subjects have different within-subject distributions and that these differences 
are not completely represented by the averaging the features over epochs, particularly for 
the zero means and RMSA (see Supplemental Material).  In an effort to capture these 
distributions with a simple number, we computed a new measure defined as the ratio of 
RMSA variance (calculated within subject, first averaged over derivations, then 
calculated over epochs) to zero-crossing variance. We found that this ratio was 
significantly different between the IS and control groups for both wake and sleep.  As 
shown below, this metric improved classification slightly, although not significantly. 
However, it did not adequately capture the differences between IS and control subjects 
that become apparent when collectively examining calculated features from all epochs.  
Such analysis will demand more complex tools, and is beyond the scope of this study.  
 
3.5 Comparison of metrics reveal that they fall into two groups 
Of the ten features we have examined, it is likely that there is some redundancy in 
the electrophysiological characteristics they capture.  For example, RMSA and LL both 
reflect information about voltage amplitude, though the two measures are not precisely 
the same; consider, if the voltage trace for a particular epoch consisted of a shape like a 
sigmoid with a sharp change in the center, RMSA would be large at almost every point 
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due to the large absolute distance from zero, while line length would be small due to the 
small variation between subsequent points. However, in most cases, we expect the two 
measures to be correlated.  To examine this, we consider comparisons between different 
pairs of measures, and determine how well these different measure correlate (Fig 4).  
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Figure IV.4. Metric cross-correlation and scatter plot comparisons of metrics in wake and sleep show several 
features are highly correlated.  
A Cross correlation analysis of metrics shows they fall into two distinct groups, within 
which there is high correlation. RMSA, Line Length, and all frequency band spectral 
powers are highly positively correlated. Zero crossings are highly positively correlated to 
local maxima and minima, and highly negatively correlated to weighted network density. 
Weighted network density and local maxima and minima do not show a strong 
correlation. Binary density is not correlated with other features. Zero crossings are 
positively correlated with higher frequency bands and less with lower frequency bands, in 
order.  Local maxima and minima show this trend as well, though less strongly. B RMSA 
and delta frequency power show a strong positive correlation (IS wake in blue, IS sleep in 
green, control wake in red, control sleep in black). C RMSA and line length show a 
strong positive correlation, but less so. D Zero crossings have a negative correlation with 
weighted network density. 
 
Computing the cross correlation between all pairs of metrics reveals that there are 
broadly two categories into which the measures fall (Fig 4A, and Supplementary 
Materials).  One category includes root mean squared amplitude, line length, and the 
frequency domain metrics, in particular delta power, all of which are highly positively 
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correlated.  The second category includes zero crossings, local maxima and minima, and 
weighted network density.  Zero crossings are positively correlated with local maxima 
and minima and negatively correlated with weighted network density, while local 
maxima and minima and weighted network density do not appear to be as strongly 
correlated with each other.  Zero crossings also exhibit an inverse correlation with the 
frequency of the power spectra; the number of zero crossings is positively correlated with 
higher frequencies, such as in the beta range, and negatively correlated with lower 
frequencies, such as in the delta range. This is consistent with the intuition that a higher 
frequency rhythm will tend to cross zero more than a lower frequency rhythm, and thus 
result in more zero crossings. We see a similar but less pronounced relationship between 
local maxima and minima and the frequency of the power spectra.  In Figure 5 we further 
illustrate some of these relationships by plotting the values of one measure against 
another for each patient for three example cases.  RMSA and delta power possess a 
strong positive linear relationship in wake and sleep (Fig 4B).  RMSA and line length 
also possess a positive linear relationship, though less so than RMSA and delta power 
(Fig 4C).  Weighted network density and zero crossing have a clear negative linear 
relationship in wake and sleep (Fig 4D).   
We interpret these relationships between the different measures as follows. The 
category including RMSA, line length, and the frequency domain features all capture 
aspects of the high amplitude, low frequency voltage traces that occur in hypsarrhythmia, 
and therefore are linearly correlated with one another.  The second category, which 
includes zero crossings, local maxima and minima, and weighted network density. Both 
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zero crossing and local maxima and minima may be more strongly associated with 
aspects of high frequency rhythms, than low frequency rhythms. Therefore, these 
measures may capture different features of the data that are unrelated to the low 
frequency rhythms characteristic of hypsarrhythmia. The interpretation of the weighted 
network density is more complex. Typically, lower frequency rhythms are associated 
with increased functional connectivity, while higher frequency rhythms are associated 
with reduced functional connectivity [167,168].  The observed negative correlation 
between weighted network density and zero crossing – which increase with frequency -  
is consistent with this phenomena.  We note that the binary density does not strongly 
correlate with any other metric, and moreover does not strongly distinguish between IS or 
control groups, is made up of very sparse networks, and also changes its relationship 
between the two groups between wake and sleep.  Since every other metric retains a 
consistent relationship between IS and control over both wake and sleep, either the binary 
density is not a useful metric in this instance, or it is measuring a subtle feature that is not 
obvious in any of the other features.   
 
3.6 Classification of patients using these metrics allows for a high degree of separation 
We begin by using all nine features (excluding binary density) and the patient age 
to construct a classifier for these data. A linear classifier performed using nine of the 
features, excluding binary density, and including age, coupled with a 10-fold validation 
resulted in an average specificity for IS of 65.1% and selectivity for control of 93.6% for 
wake, and an average specificity of 74.2% and an average selectivity of 98.4% for sleep.   
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While this classifier demonstrates high selectivity, the sensitivity is lower than expected, 
an important point when detecting disease states, as sensitivity is arguably more 
important than specificity. We note that, while the 10-fold validation does not perfectly 
validate the universality of the findings, it does verify that the effectiveness of the 
classifier is distributed throughout the datasets of the groups, rather than being driven by 
a particular outlying subset.   
When selecting features for use in discriminating between two groups, it is 
tempting to gather as many as possible, regardless of redundancies.  However, doing so 
may result in negative consequences, if the amount of data is not adequate, as dictated by 
the curse of dimensionality.  This states that as features are added, the number of 
observations required increases exponentially [169,170].  This is a particularly crippling 
problem if the number of datasets used is low, as is the case here for clinical recordings 
from this rare disease population.  In addition, an increase in the number of features adds 
computational complexity, which may be costly depending on the amount of data and 
equipment used.  Most importantly, features that are redundant, meaningless, or 
misleading obfuscate clear interpretation of the data and possibly the significance of the 
findings.  The first step before classification is thus to explore if a smaller but equally 
effective set of features can be used, also known as ‘dimensionality reduction’.   
There are two primary methods of dimensionality reduction, feature extraction 
and feature selection. Feature extraction methods, such as principle components analysis 
(PCA), do not reduce the number of features but construct a new set of features that uses 
linear combinations of the original features to optimize the variance explained, so that a 
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smaller number of the new features may then be chosen to adequately explain the data.  
This is a good way to determine how well a smaller number of dimensions may explain 
the data. Feature selection methods, such as sequential feature selection or stepwise 
regression, select a subset of the already existing features for use in model construction. 
In stepwise regression a linear model is created using the selected features to explain the 
data, and features are added or subtracted from the model, keeping only those that add the 
most significance to the classification. Both of these methods of dimensionality reduction 
are usually coupled with a method of ranking the variables by their effectiveness.  
Using a PCA we found that 85.0% of the wake data variance and 82.6% of the 
sleep data variance may be explained by the top two principal components, and 92.7% of 
the wake data and 91.3% of the sleep data may be explained by the top three principal 
components.  It is important to note that PCA does not distinguish between IS and 
control, but merely separates all the data along the axes of greatest variance.  The 
presumption is that there is greater variance between the two condition groups than 
within them. In plotting the primary two principal components we see that this 
presumption is borne out, and that it is possible to separate IS from control subjects with 
high success using a reduced number of components (Fig 5A Wake at top, Sleep at 
bottom). An almost complete separation of IS and control is achieved in wake (top), and 
very few misclassifications in sleep (bottom).   
  
	  	  
111 
 
Figure IV.5. PCA and Classification using two features successfully separate IS (blue) and control (red) subjects.  
Partial component analysis (PCA) and Linear Discriminant Analysis (LDA) distinguish 
the IS and controls groups. A Scatter plots of the PCA of IS and CNTRL in wake (top) 
and N2 sleep (bottom) conditions. PCA was performed using as features: Weighted 
network density, Zero Crossings, Local Maxima & Minima, Line Length, RMSA, Delta, 
Theta, Alpha, and Beta Power Spectra. The top two components effectively classify IS 
and CNTRL, with almost complete separation in wake and only three IS and 
approximately five CNTRL mis-categorized. B LDA Classification of IS and control 
using weighted network density and RMSA wake (top) and N2 sleep (bottom) C LDA 
Classification using weighted network density and delta frequency power for wake (top) 
and N2 sleep (bottom).  
 
The next step is to find the optimal subset of features that will maximize the 
correct classification of IS and control subjects, by way of feature selection.  This is 
somewhat complicated by the presence of both wake and sleep conditions.  It is possible 
to collect all the data together into a single group, but that would add an unnecessary 
confound or term to the analysis.  Instead we perform feature selections on wake and 
sleep independently, and use this to guide the selection of features.  
A simple approach to ranking the descriptiveness of feature is to assume that each 
feature is independent and compute a two-way t-test (Matlab function rankfeatures.m).  
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We find for wake data a feature list, from highest to lowest, of: RMSA, delta PS, local 
maxima and minima, weighted network density, line length, alpha PS, zero crossings, 
beta PS, theta PS, and age. For sleep data the feature list is: local maxima and minima, 
zero crossings, RMSA, delta PS, weighted network density, theta PS, alpha PS, line 
length, beta PS, and age. This however does not account for redundant information, 
which is necessary for using several features together. To do so we perform two feature 
selection procedures.  
We first conducted a forward sequential feature selection (MATLAB function 
sequentialfs.m) using a linear discriminant analysis classifier with a 10-fold cross 
validation to calculate criteria for inclusion or exclusion from the predictive model. This 
returned an optimal feature set for wake data including RMSA and weighted network 
density, and an optimal feature set for sleep data including delta PS and weighted 
network density. A similar stepwise feature selection performed using the Matlab 
function stepwisefit.m, which uses multilinear regression to test for model fit, returned 
RMSA and alpha PS as features for wake data, and weighted network density and theta 
PS for sleep data.  
Alpha PS and theta PS effectiveness as classification features was limited to one 
of wake or sleep, compared to RMSA, delta PS, and weighted network density, which 
were similarly effective for both conditions.  Using only the RMSA and the weighted 
network density as features, the same linear discriminant analysis classifier with 10-fold 
cross validation demonstrated an average sensitivity for IS of 89.0% and an average 
specificity for control of 100% in wake, and an average sensitivity for IS of 81.9% and an 
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average specificity for control of 97.6% in sleep. Using delta PS and the weighted 
network density as features, the classifier had an average sensitivity for IS of 84.4% and 
an average specificity for control of 99.6% in wake, and an average sensitivity for IS of 
84.3% and an average specificity for control of 97.8% in sleep. The group separation 
using these two features is even better than that obtained with PCA (figure 6B,C). 
Interestingly, this is a much better sensitivity and specificity than obtained using all 
features, and the addition of a single feature caused the effectiveness of the classifier to 
decrease.  However, a large number of combinations of two or three features, generally 
including at least one from each of the two groups discussed, returned almost comparable 
results.  This phenomenon is potentially due to relatively low number of datasets 
available for classification (13 or 16 IS, rather than hundreds), and the effect of the curse 
of dimensionality. It must also be remembered that all classification processes are prone 
to over-fitting, especially if a separate large and separate data set is not used for 
independent validation.  Validation data for this rare disease were unavailable for this 
study. As such our classification results could result by chance, or be obscured by an 
outlier. Also of note, better classification performance, with specificity above 90%, was 
possible using quadratic discriminant analysis.  However, it was deemed that this type of 
analysis was probably not as robust as the linear discriminant analysis described here.   
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4. DISCUSSION 
In this manuscript, we described an approach to identify electrophysiological 
biomarkers for the quantitative identification and characterization of infantile spasms in 
children. We characterized ten features deduced from network domain, frequency domain 
and time domain measures that distinguished between IS and control groups.  All ten 
features were found to show significant differences between IS and control, even when 
accounting for the confound of age. While age did have a small effect on some of the 
features, significant differences in most measures remained between the two groups.  We 
showed that nine of the ten features could be broadly collected into two main intra-
correlated groups.  These features could be used in a linear classifier to perform a 
discriminant analysis that, tested using 10-fold validation, produced an average of greater 
than 65.1% sensitivity and greater than 93.6% specificity for detecting IS.  A 
discriminant analysis using just two features produced an average of greater than 84.3% 
sensitivity and an average of greater than 97.6% specificity for detecting IS. These results 
suggest that specific and robust electrophysiological biomarkers of IS exist, and may 
provide an additional tool for quantitative diagnosis of IS, especially if it is determined 
that they are parametrically related to severity of IS.   
These results are consistent with expectations for these data, but – due to the 
complex nature of these signals – are far from obvious. The EEG recorded from patients 
with IS exhibit intervals of background hypsarrhythmia and ictal electrodecrement in 
unpredictable proportions, in some instances with, and others without noticeable 
electrodecrement, and hypsarrhythmia is indicated by high amplitude while 
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electrodecrement by reduced amplitude.   It is promising that IS data in this study exhibit 
a noticeable difference from control subjects.  The main purpose of this study was to 
investigate which quantitative metrics were most reliable and significant in distinguishing 
between the IS and control groups with particular attention to characteristics of 
hypsarrhythmia, whether any metrics separated IS in such a way that might be correlated 
to severity of symptoms, to obtain quantitative measurements of what the differences in 
these metrics were, and how they might be used as electrophysiological biomarkers to 
automatically classify IS from control subjects. Each metric was thus examined for 
significance and classification potential.  
 
4.1 Functional network features of IS 
Inference and analysis of functional networks in epilepsy is an active but nascent 
area of research [171]. Functional networks are presumed to reveal the transient patterns 
in communication between brain regions [59]. Epilepsy has been postulated to be a 
disorder of structural and therefore functional communication between various brain 
regions, has been correlated with network alterations [29,172], so investigation of 
functional networks is a natural choice of analysis. Although epilepsy is still 
incompletely understood, it is thought that causal structural disruptions can vary 
considerably between individuals, even with the same particular condition. Because of 
that, it is important to analyze properties derived from electrophysiological measurement 
of brain activity, which is the gold standard for how neurologists diagnose distinct 
pathologies of epilepsy.  One of the most frequently reported functional network finding 
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in seizure is an increase in connectivity [29]. We found that a weighted network density 
was slightly but significantly higher in IS than control groups, both during wake and 
sleep, while a binary network density was lower during wake, but higher during sleep. 
Weighted network density results correlated with other measure results and separated IS 
and control populations, while  binary density did not.  We therefore included the 
weighted network density in the classification, but not the binary density. 
 
4.2 Frequency domain features of IS 
We found that the spectral power in IS at each canonical frequency band was 
significantly higher than in control subjects, though this difference was not statistically 
significant at beta frequencies for wake when accounting for age.  As stated elsewhere, 
this result is consistent with the notion of hypsarrhythmia as  a large amplitude voltage 
signal with impact across the frequency bands. Future work may assess the relationship 
between power and severity of IS.   
 
4.3 Time domain features of IS 
Time domain features are common tools investigated for potential in detecting 
seizures or characterizing epilepsy.  They directly relate to the features used by 
neurologists in characterizing and diagnosing epilepsy.  In this study, we looked for 
simple metrics that might contain quantitative information relating to the most 
stereotyped characteristics of hypsarrhythmia, the defining characteristic of IS.  We 
settled on four metrics: zero crossings, number of local maxima and minima, line length, 
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and root mean squared amplitude. All four metrics reveal significant differences between 
IS and control, both during wake and sleep.  IS was lower than control for both zero-
crossings and local maxima and minima, while IS was higher than control for line length 
and RMSA.  It is not possible to clearly elucidate precisely which feature differences in 
EEG these metrics measured without an in-depth analysis separating IS EEG recordings 
into distinguishable periods, defining which epochs contained high amplitude voltages, 
which contained electro-decrement, which included multi focal spikes, etc.  That was not 
the focus of this study.  However we expect that higher line length and RMSA in the IS 
group is a reflection of the presence of high amplitude activity during hypsarrhythmia. It 
is also possible that lower zero-crossings and local maxima and minima manifest during 
the large amplitude slow rhythms characteristic of hypsarrhythmia, or reflect reduced 
activated present in electrodecrement.  If they were related to hypsarrhythmia, it would 
be surprising that they show such low correlation with RMSA and line length.  Such low 
frequency rhythms are typically associated with lower complexity of brain function [27]. 
 
4.4 EEG classification of IS 
A primary goal of this work was to use the scalp EEG features to propose a 
biomarker for IS and hypsarrhythmia.  Despite prominent characteristics, hypsarrhythmia 
assessment exhibits poor inter-rater reliability, which has been identified as a threat to 
clinical trial validity [8].  In addition, clinical diagnosis tends to be binary, and does not 
give information that could be used to grade severity or perhaps subtype of IS.  
Quantitative biomarkers of IS features could assist with this.   
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Nine of the ten chosen metrics were found to show consistent, significant 
differences between the IS and control group, however many of these metrics were 
correlated and could be divided into two groups.  One group included zero crossings, 
local maxima and minima, and weighted network density.  These features may reflect a 
reduction in structured brain activity of IS subjects during hypsarrhythmia or 
electrodecrement.  The other group included line length, root mean squared amplitude, 
and the four power spectra measures, most notably the delta power.  These features are 
most likely related to the high amplitude voltage fluctuations characteristic of 
hypsarrhythmia.  Of the power spectra metrics, the delta band power was most correlated 
with the other metrics, and as high amplitude hypsarrhythmia activity is known to occur 
in delta frequency is likely the greatest spectral measure of hypsarrhythmia.  Using just 
one metric from each of these groups was enough to separate IS from control subjects 
with a high degree of effectiveness (Fig 5 B,C), and could lead to a parameterization of 
the severity of IS.  Using linear discriminant analysis, and a 10-fold validation to test 
performance, we found our features were able to classify over 84.3% of IS subjects and 
97.8% of control subjects correctly on average.  Combined with existing diagnosis 
procedures, a biomarker or biomarkers deduced from scalp EEG would provide an 
additional cost-effective and relatively straightforward procedure to improve IS 
diagnosis, estimate severity, and possibly predict outcome.   
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5. CONCLUSIONS 
Quantitative analysis of brain activity through EEG measurements is a promising 
and rapidly growing field. Application of these tools are rapidly being applied to many 
different cognitive disorders [28,173]. These tools are increasingly being applied to 
quantitatively characterize features in epilepsy that until now have been the domain of 
neurologist expertise. In the future, more advanced machine learning tools may 
characterize EEG features with equal or greater effectiveness and consistency than the 
human eye.  A step in that direction is quantitatively determining features that reflect 
visual characteristics of EEG analysis. In this work, we calculated ten EEG metrics from 
a large group of cryptogenic IS subjects aged 2-16 months in wake and sleep state and 
compared these metrics to age matched controls, and tested the effectiveness of these 
metrics at classifying subjects into their respective groups. We based our choice of 
metrics on classic quantitative brain activity measures, and the stereotyped characteristics 
of IS including hypsarrhythmia and electrodecrement.  Nine of the 10 metrics chosen had 
highly significant and consistent differences between IS and control in wake and sleep 
states.  These metrics could be broadly categorized into two groups, which were together 
highly effective at classifying IS and control subjects.  We have demonstrated nine 
biomarkers that significantly differentiate between a population of IS and control 
subjects: weighted network density, spectral power in four canonical frequency bands, 
the number of zero crossings, local maxima and minima, line length, and root mean 
squared amplitude.  Of these, the combination of root mean square density or spectral 
power in the delta frequency range with weighted network density was found to perform 
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the best in classifying IS from control subjects. This is an important tool for current 
clinical diagnosis.  This work also provides motivation for future studies of the 
effectiveness of these metrics in predicting actual outcome of IS subjects to treatment. 
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CHAPTER V. CONCLUSION 
The research presented in this dissertation explores the possibility of finding 
quantitative biomarkers from electrophysiological recordings.  Most current methods for 
diagnosing brain disorders are subjective, rely on expert clinical skill, and do not provide 
parametric information about disease type or severity.  Using a number of mathematical 
techniques, we were able to extract meaningful quantitative features from patients with 
ASD, patients with IS, and control subjects. These features served to distinguish patients 
clinically diagnosed with disease from healthy controls, and provided clues towards a 
parametric measures of the extent/severity of the disease being examined.   
In general, Not only does this improve potential clinical implementation, but 
excessively complex data manipulations might lead to features that are too removed from 
data to be easily interpretable.  
A major hurdle to develop reliable EEG biomarkers of disease is to isolate 
features that not only are descriptive, quantitative, and informative, but to make these 
features robust for application in other situations. To that end, we opted for traditional 
methods to characterize EEG features (for example, the power spectrum, number of zero 
crossings, and correlation) rather than more sophisticated characterizations of brain 
activity (e.g., information measures). The methods employed here have facilitated 
understanding in many areas of neuroscience, and – because they are well understood - 
help facilitate a direct interpretation of the EEG data. We therefore expect these results to 
have broad applicability to the analysis of EEG recorded from patients with ASD and IS. 
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1. Innovation and Impact 
1.1 Biomarkers of ASD 
While much research is conducted on ASD, relatively little is conducted that 
focuses on EEG or specifically on children.  Thus, the results presented in this thesis 
represent a significant addition to the collective knowledge in this area, and potentially 
offer a useful tool to augment clinical diagnosis and future research.  In addition, few 
EEG studies of ASD implement a large number of subjects to support a method of 
validation that divided the data into testing and validation groups.  Our results 
demonstrate the importance of the validation of candidate EEG biomarkers, and 
emphasize the need for methods that facilitate comparison between studies.  
 
1.2 Biomarkers of ASD in sleep 
 While no significant biomarkers were found to distinguish ASD from control 
subjects in stage 1, 2, or 3 sleep, we propose that this negative result further advances the 
understanding of ASD.  In general, sleep state EEG data presents numerous advantages 
for analysis, including the reduction of motion or blink artifacts and a potentially more 
consistent pattern of cognitive activity between patients.  It is possible that the lack of 
significant results indicates that the electrophysiological differences found in the awake 
state relate to functional activity found only in wakefulness.  This remains a subject for 
future study.  
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1.3 Biomarkers of IS 
 While a significant difference between IS and control subjects is not surprising, 
the results reported here represent one of the first quantitative measurements of this 
difference using objective electrophysiological features.  These results are important and 
relevant for two reasons. First, the standard clinical diagnosis of IS relies on the 
subjective visual analysis of EEG data, and suffers from low inter-rater reliability [8]. A 
quantitative measure may help improve the reliability of diagnosis. Second, the 
quantitative features may help stratify patients according to disease severity and form the 
basis for studies relating EEG features to prognosis.  
 
2. Future Directions 
2.1 Detailed analysis of validated ASD biomarkers 
The biomarkers found in Chapter II may be robust indicators of ASD, but further 
investigation is warranted for several reasons.  It is important to remove any doubt that 
the measures found are due in any part to motion, attention, or some behavioral 
phenomenon.  It is also worthwhile to examine if the biomarkers are related to severity of 
ASD. To test these traits, further research should be conducted using a large sample of 
ASD subjects with measured severity on some current scoring test against age matched 
controls, under both resting state condition (with eyes closed, and with eyes fixated on a 
cross), as well as under tasks that involve faces or other ASD specific indicators.  If these 
tests do validate the biomarkers, it is with greater certainty that these may be used in the 
robust method demonstrated here.  
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2.2 Validation of electrophysiological biomarkers of hypsarrhythmia 
Using the features found in the IS research of Chapter IV, we will undertake a 
continuing research study using cryptogenic and symptomatic IS subjects with data 
collected before drug intervention, and data collected after drug intervention and after 
patient outcome has been established. Currently, there exists no method to predict 
whether a child with IS develop normally or will suffer from severe cognitive deficits. He 
will test the hypothesis that the EEG features identified in Chapter IV, applied to patients 
before drug intervention, will help predict patient outcome. A quantitative measure to 
predict outcome would have great clinical significance.  
Beyond the current and planned studies, future research in diagnostic biomarkers 
will eventually have to extend beyond group-level comparisons and instead stratify 
individuals by relating EEG characteristics with core behaviors (in the case of ASD, with 
language, social communication skills, executive function, intellectual function, or other 
distinguishing traits). EEG measures such as spectral power, network correlations, and 
time domain features vary continuously over a range, and relate to typical development, 
so hold immense potential to identify clinically meaningful subgroups within the 
diversity of neurodevelopmental disorders [9]. Ultimately, the next step may be 
biomarkers of risk prediction, revealing information about the complex interaction 
between genetic susceptibility and environmental influence. It is possible that aberrant 
clinical connectivity, neural integration, and other measures precede clinical evidence of 
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neurodevelopmental or neurological disorder, and will allow clinical intervention before 
negative effects take place.  
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APPENDIX A: CHAPTER II SUPPLEMENTARY MATERIALS 
 
 
 
Supplementary Fig II.1. Cross correlation network density using Transverse Bipolar and Hjorth-Laplacian 
reference montages.   
Cross correlation network density was examined using transverse bipolar (top) and 
Hjorth-Laplacian (bottom) reference montages as well as longitudinal bipolar for wake 
and sleep data (wake data shown).  The results found were qualitatively similar those 
found using the longitudinal bipolar (double banana) montage.   
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WPLI Analysis 
 
 
Supplementary Fig II.2. Application of the weighted phase-lag index produces similar density results.   
WPLI analysis on the alpha frequency range (8-12 Hz).  (Left) Full network density of 
ASD (blue) and control (red) groups is not significantly different (p > 0.1). (Right) Mask 
density reveals a significant difference (p=0.036) between the ASD group (blue) and the 
control group (red). 
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Supplementary Fig II.3. Analysis of biomarkers as a function of ASD severity.   
A scatter plot of ASD subjects coded by severity (black = severe ASD, blue = moderate 
ASD, green = mild ASD) and control subjects (red) illustrates a possible correlation 
between severity and the biomarkers of mask score (vertical axis) and alpha ratio 
(horizontal axis) found in this study. 
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APPENDIX B: CHAPTER IV SUPPLEMENTARY MATERIALS 
 
Supplementary Fig IV.1. Time domain measures by channel 
A Zero-crossing rate, B local maxima and minima, C line length, D RMSA. Bar plots for each 
metric by derivation are in the order of IS wake (top), control wake (2nd from top), IS sleep (2nd 
from bottom), and control sleep (bottom). Individual datasets are displayed as black dots over the 
bars, which represent group means. Gray bars represent confidence intervals of 2 standard errors. 
Derivations are listed on the bottom, but go in the order of (from 1 to 10), Left anterior (1) to Left 
posterior (5) followed by Right anterior (6) to Right posterior (10) 
 
 
	  	  
130 
 
Supplementary Fig IV.2. Frequency domain measures by channel 
A Delta frequency Power, B Theta frequency Power, C Alpha frequency Power, D Beta 
frequency Power. Bar plots for each metric by derivation are in the order of IS wake (top), control 
wake (2nd from top), IS sleep (2nd from bottom), and control sleep (bottom). Individual datasets 
are displayed as black dots over the bars, which represent group means. Gray bars represent 
confidence intervals of 2 standard errors. Derivations are listed on the bottom, but go in the order 
of (from 1 to 10), Left anterior (1) to Left posterior (5) followed by Right anterior (6) to Right 
posterior (10) 
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Supplementary Fig IV.3. Topographic bar plot of Time domain measures by derivation, WAKE 
A Zero-crossing rate, B local maxima and minima, C line length, D RMSA. Top of the plot is 
anterior of the head, bottom of the plot is posterior. IS is blue while control is red. Individual 
datasets are displayed as black dots over the bars, which represent group means. Gray bars 
represent confidence intervals of 2 standard errors. P-values less than 0.05 are in red.  
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Supplementary Fig IV.4. Topographic bar plot of Time domain measures by derivation, SLEEP 
A Zero-crossing rate, B local maxima and minima, C line length, D RMSA. Top of the plot is 
anterior of the head, bottom of the plot is posterior. IS is blue while control is red. Individual 
datasets are displayed as black dots over the bars, which represent group means. Gray bars 
represent confidence intervals of 2 standard errors. P-values less than 0.05 are in red.  
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Supplementary Fig IV.5. Topographic bar plot of frequency domain measures by derivation, WAKE 
A Delta frequency Power, B Theta frequency Power, C Alpha frequency Power, D Beta 
frequency Power. Top of the plot is anterior of the head, bottom of the plot is posterior. IS is blue 
while control is red. Individual datasets are displayed as black dots over the bars, which represent 
group means. Gray bars represent confidence intervals of 2 standard errors. P-values less than 
0.05 are in red.  
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Supplementary Fig IV.6. Topographic bar plot of frequency domain measures by derivation, SLEEP 
A Delta frequency Power, B Theta frequency Power, C Alpha frequency Power, D Beta 
frequency Power. Top of the plot is anterior of the head, bottom of the plot is posterior. IS is blue 
while control is red. Individual datasets are displayed as black dots over the bars, which represent 
group means. Gray bars represent confidence intervals of 2 standard errors. P-values less than 
0.05 are in red.  
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Supplementary Figure IV.7. Cross correlational matrices of features 
A IS Wake, B IS Sleep, C control Wake, D control Sleep. Cross correlation matrices of ten 
features. Several features show high correlation with each other in both IS and control, in wake 
and in sleep.  
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Supplementary Figure IV.8. T-test comparison of  Density for IS and control, controlling for age. 
A Binary density Wake, B Binary density Sleep, C weighted density Wake, D weighted density 
Sleep. IS is blue while control is red. Individual datasets are displayed as black dots over the bars, 
which represent group means. Gray bars represent confidence intervals of 2 standard errors. P-
values less than 0.05 are in red. In the scatter plot age ranges from 2 to 16 months, and linear 
model fit lines indicate trends with age.  However a trend-line does not signify that it is a 
significant trend.  
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Supplementary Figure IV.9. T-test comparison of  Time domain features for IS and control, controlling for age. 
A Zero Crossing Rate, B local maxima and minima, C line length, D RMSA. Left are Wake data, 
and Right are sleep data. IS is blue while control is red. Individual datasets are displayed as black 
dots over the bars, which represent group means. Gray bars represent confidence intervals of 2 
standard errors. P-values less than 0.05 are in red. In the scatter plot age ranges from 2 to 16 
months, and linear model fit lines indicate trends with age.  However a trend-line does not signify 
that it is a significant trend.  
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Supplementary Figure IV.10. T-test comparison of  frequency domain features for IS and control, controlling 
for age. 
A Delta frequency power, B Theta frequency power, C Alpha frequency power, D Beta 
frequency power. Left are Wake data, and Right are sleep data. IS is blue while control is red. 
Individual datasets are displayed as black dots over the bars, which represent group means. Gray 
bars represent confidence intervals of 2 standard errors. P-values less than 0.05 are in red. In the 
scatter plot age ranges from 2 to 16 months, and linear model fit lines indicate trends with 
age.  However a trend-line does not signify that it is a significant trend.  
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Supplementary Figure IV.11. Linear Classification using Delta frequency power and the ratio of RMSA 
variance over zero-crossing variance (nm). 
A Wake, B Sleep.  Classification using the log Delta frequency power and the ratio of RMSA 
variance of zero-crossing variance.  IS datasets are in blue, while control are in red.  Note that the 
control datasets are concentrated to a small area while the IS datasets are more distributed.  There 
is a possibility that this could indicate real differences within the IS group, which if true could be 
used for measuring severity of condition.  
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